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Abstract 
In 2008 the European Food Safety Authority, EFSA, reported that Campylobacter was one of 
the most frequently observed bacterial gastrointestinal pathogen in humans. Poultry meat is an 
extremely important foodborne source of Campylobacter spp. Although self-limiting, 
campylobacteriosis occasionally requires treatment and macrolides and fluoroquinolones are 
the drugs of choice. 
 For the past few decades resistant C. jejuni and C. coli strains have emerged at an alarming 
rate due, at least partly, to the large-scale use of these agents in food production animals and 
passed on to humans through poultry meat products. 
 The purpose of this work was the phenotypic and genotypic characterization of isolates from 
two different origins: poultry and human, in order to perceive the general panorama regarding 
antimicrobial resistance for C. jejuni and C. coli strains in Portugal.  
Disc diffusion tests results provided comprehensive information about antimicrobial resistance 
for the tested products and made selection of multiple drug resistant strains possible. Antibiotic 
and disinfectant minimum inhibitory concentrations were determined and the effect an efflux 
pump inhibitor in restoring ciprofloxacin susceptibility was analyzed. High resistance frequency 
to fluoroquinolones was observed reaching, for ciprofloxacin, levels as high as 92% (retail 
isolates), 30% to 40% of studied isolates were erythromycin resistant and resistance patterns 
for tetracycline ranged from 37% to 91%. Human isolates showed high level percentage of 
resistant isolates to both therapeutic alternatives. Multiple drug resistance was one of the major 
issues to be considered in the present work, which occurred in 86.3% to 93.2% of tested 
strains. Erythromycin and ciprofloxacin high level resistance (HLR) strains were among the 
selected isolates, and the respective HLR associated point mutations, were detected. The effect 
of the efflux pump inhibitor (PAβN) on ciprofloxacin resistance revealed that susceptibility to this 
antibiotic could be restored for mostly all, except for HLR ciprofloxacin strains. 
 
 
 
 
 
 
 
Keywords: Campylobacter, fluoroquinolones, erythromycin, multiple-resistance, efflux pump inhibitors. 
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Resumo 
Campylobacter spp. é reconhecido como um dos principais agentes responsáveis por 
gastroentrites de etiologia bacteriana em humanos. Entre as espécies deste género 
patogenicamente mais relevantes incluem-se Campylobacter jejuni e Campylobacter coli sendo 
que a primeira é responsável por cerca de 80 - 90% dos casos de campilobacteriose 
registados, enquanto os restantes casos são, na sua maioria, da responsabilidade de C. coli 
(Fitzgerald et al., 2008). 
 
Tipicamente os casos de campilobacteriose são auto-limitantes e não requerem terapêutica 
antimicrobiana. Esta é apenas efectivamente necessária num relativamente reduzido número 
de situações: Caso a infecção ocorra em indivíduos imunocomprometidos, na eventualidade de 
se verificarem complicações secundárias extra intestinais ou em caso de persistência dos 
sintomas gastrointestinais (Nachamkin et al., 1998; Skirrow et al., 2000). 
 
Os macrólidos e fluoroquinolonas surgem como os principais agentes terapêuticos indicados na 
resolução das situações anteriormente descritas. A resistência a estes agentes terapêuticos 
tem, no entanto, crescido a um ritmo alarmante nas últimas décadas verificando-se 
inclusivamente resistências simultâneas a diferentes grupos de antibióticos por parte de 
estirpes isoladas numa das principais fontes de infecção como sucede com a carne de aves 
(Vliet & Ketley, 2001; Gibreel et al., 2006). 
 
Os macrólidos são antibióticos bacterioestáticos que actuam por inibição da síntese proteica 
ligando-se à subunidade 23S rARN da subunidade ribossomal 50S, onde, perante a ocorrência 
de mutações pontuais, se verifica a alteração do alvo deste agente terapêutico inibindo assim a 
sua actividade. Estas mutações ocorrem ao nível do domínio V do gene 23S rARN, nas 
posições 2075 e 2074 ocorrendo, de forma geral, respectivamente uma transição (A2075G) e 
uma transversão (A2074C). Tipicamente esta primeira mutação pontual é predominante e será 
por isso um dos alvos neste estudo (Engberg et al., 2001; Gibreel & Taylor, 2006). 
 
As fluoroquinolonas são agentes antimicrobianos de largo espectro que actuam por inibição 
das topoisomerases. No caso de Campylobacter spp. é particularmente importante o seu efeito 
na topoisomerase II, ADN girase responsável pela manutenção do supercoil negativo da dupla 
hélice da molécula de ADN durante a replicação e transcrição. A ocorrência de uma mutação 
pontual ao nível da região determinante de resistência a quinolonas (QRDR, do ing. Quinolone 
Resistance Determining Region) afectando o aminoácido 86Thr (Thr-Ile), é o principal 
mecanismo de desenvolvimento de resistência a fluoroquinolonas. Não existem actualmente 
evidências da existência da topoisomerase IV em Campylobacter (Engberg et al., 2001; 
Fàbrega et al., 2008). 
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Para além da ocorrência de mutações pontuais observa-se o desenvolvimento de resistência, 
tanto a fluoroquinolonas como a macrólidos devido à actividade de mecanismos de efluxo. A 
bomba de efluxo CmeABC pertencente à família de transportadores RND (do ing. Resistance 
Nodulation Division), inicialmente descrita por Pumbwe e Piddock (2002) e Lin et al. (2002) 
encontra-se actualmente associada a mecanismos de resistência intrínseca e a baixos nível de 
resistência, LLR (do ing. Low Level Resistance) a estes agentes terapêuticos. A actividade da 
bomba de efluxo é inibida na presença do inibidor de bombas de efluxo, EPI (do ing., efflux 
pump inhibitor) (Webber & Piddock, 2003; Akiba et al., 2006; Piddock, 2006). 
 
O aumento de estirpes que apresentam resistência múltipla é actualmente uma relevante fonte 
de preocupação sob o ponto de vista clínico, sendo necessário determinar se a resistência 
apresentada por estirpes de origem animal se estende a outros antimicrobianos, 
nomeadamente desinfectantes uma vez que estes são utilizados frequentemente nos 
programas de higienização de matadouros, nas salas de desmancha de onde provêem as 
carcaças e peças de frango para consumo humano. 
 
O objectivo deste trabalho prendia-se com a caracterização fenotípica e genotípica de isolados 
de Campylobacter de diferentes origens, amostras de produtos para consumo humano e 
amostras com origem em pacientes com campilobacteriose, de forma a captar o estado actual 
deste importante agente em relação a resistências a antimicrobianos tanto na carne para 
consumo humano como no próprio homem, em Portugal. Pretendia-se igualmente avaliar a 
resposta dos isolados a dois desinfectantes diferentes, utilizados rotineiramente na limpeza e 
desinfecção dos matadouros e salas de desmancha. Por fim era também pretendido apreciar o 
efeito de um inibidor de bomba de efluxo, PAβN (fenilalanina arginina β-naftilamida) no 
restabelecimento da susceptibilidade, neste caso especifico, à ciprofloxacina. 
 
Tendo por base os objectivos descritos foram seguidas as metodologias que se consideraram 
mais adequadas. A identificação dos isolados foi inicialmente feita pelo teste do hipurato e 
posteriormente corroborada por PCR multiplex, de acordo com Dennis et al. (1999) e 
Samorsornsuk et al. (2007). Testes de susceptibilidade a antibióticos por difusão de disco 
foram realizados, de modo a proceder à elaboração dos perfis de resistência dos isolados 
obtidos, provenientes de amostras de frangos (pele do peito, intestino e peito de frangos de 
produção extensiva indoor, intensiva e biológica e de carcaças de frangos ‘pronto a cozinhar’ 
adquiridas em grandes superfícies comerciais) para 11 antibióticos, eritromicina, tetraciclina, 
gentamicina, amoxacilina e ácido clavulânico, ácido nalidixíco, ciprofloxacina, norfloxacina, 
ofloxacina, trimetropim-sulfametoxazole, cloranfenicol e ampicilina. A selecção de estirpes com 
resistência múltipla era então possivel. Ás estirpes seleccionadas for aplicada a técnica de 
concentração mínima inibitória, CMI, por diluição em agar, para eritromicina, ciprofloxacina, 
tetraciclina e gentamicina, assim como para os dois desinfectantes: hipoclorito de sódio e 
cloreto de benzalcónio. A gama de concentrações para os antibióticos está de acordo com o 
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normativo CA-SFM 2010. A gama de concentrações a que os desinfectantes foram testados 
variou entre 0,5 a 32 µg/mL, de acordo com Peyrat et al. (2008). 
 
A ocorrência de mutações pontuais, nomeadamente à mutação A2075G que surge ao nível do 
domínio V do gene responsável pela subunidade 23S rRNA, tipicamente perdominante em 
comparação à ocorrência da mutação A2074C na mesma região foi testada recorredo-se á 
técnica de RFLP-PCR (Restriction Fragment Length Polymorphism) de acordo com Kurinčič et 
al., 2007. As mutações pontuais ao nível da região QRDR do gene responsável pela DNA 
girase, gyrA foram avaliadas pela técnica de MAMA-PCR (Mismatch Amplification Mutation 
Assay) de acordo com o trabalho de Payot et al. (2004). 
 
O efeito da bomba de efluxo foi avaliado na presença de diferentes concentrações de 
ciprofloxacina e de diferentes concentrações de inibidor, PAβN (Phe-Arg-β-naftilamida) 
realizado de acordo com o estudo descrito por Payot et al. (2004). 
 
Do numero total inicial de isolados, 75% tinham origem alimentar enquanto que os restantes 
tinham origem humana. Do número inicial de isolados, 258, 43% foram identificados como  
C. jejuni enquanto os restantes 57% foram identificados como C. coli. 
 
Testes de difusão de disco providenciaram a informação necessária, relativamente à 
resistência a antibióticos, para os produtos testados. Foi possível constatar uma particular 
elevada frequência de resistência às fluoroquinolonas, 58% a 92%. Para o macrólido 
eritromicina, 30% a 40% dos isolados estudados eram resistentes. Foram também identificados 
níveis de resistência para a gentamicina e tetraciclina que variavam respectivamente entre: 6% 
a 45% e de 37% a 91%.  
 
Isolados com origem em amostras de frangos de produção extensiva apresentaram, 
comparativamente aos isolados com origem em amostras de frangos de produção biológica, 
níveis mais baixos de resistência a ciprofloxacina enquanto os isolados de amostras de 
produtos prontos a cozinhar apresentavam os mais altos níveis de resistência a este 
antibiótico. O mesmo padrão de resistência foi observado para a tetraciclina onde se 
evidenciaram níveis de resistencia mais reduzidos para os isolados com origem em frangos de 
produção extensiva e os mais altos para isolados de amostras de produtos prontos a cozinhar. 
No caso especifico da eritromicina foi possível constatar, que os isolados de produtos prontos a 
cozinhar apresentavam-se mais susceptíveis (40% de isolados resistentes) que os isolados de 
frangos de produção extensiva (75% de isolados resistentes). 
 
Os isolados de amostras de fezes humanas provenientes de indivíduos com campilobacteriose 
apresentavam níveis de resistencia particularmente elevados para as alternativas terapêuticas 
tipicamente utilizadas: 32% e 37% dos isolados eram resistentes respectivamente a 
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eritromicina e à tetraciclina e mais de 70% eram resistentes à ciprofloxacina. Apenas 19% dos 
isolados apresentavam resistência a gentamicina, no entanto, devido à elevada toxicidade 
deste agente a sua aplicação é altamente limitada mas persiste enquanto alternativa 
terapêutica. 
 
A questão da resistência múltipla era um ponto fulcral no desenvolvimento desta dissertação. 
Foi possível observar que para todos os isolados testados a maioria apresentava resistência 
para 4 ou mais das 7 classes de antibióticos testadas, tipicamente para quinolonas, macrólidos, 
tetraciclina e β-lactâmicos. Constatou-se que entre 86% e 93% das estirpes testadas 
apresentavam resistencia múltipla. Estirpes de origem humana e de origem em produtos 
prontos a cozinhar não apresentaram nenhuma estirpe totalmente susceptível a todas as 
classes de antibióticos testadas. 
 
Todas as estirpes avaliadas como HLR para a ciprofloxacina e eritromicina eram portadoras 
das mutações pontuais, respectivamente gyrA (Thr86) e A2075G. As concentrações mínimas 
inibitórias mais altas foram obtidas para estirpes de origem em frangos de produção biológica. 
Para a eritromicina foi de 128 mg/L e de 512 mg/L para a ciprofloxacina. Foi também possível 
constatar algum paralelismo entre estirpes classificadas como HLR para a ciprofloxacina e os 
padrões de resistencia obtidos para os desinfectantes em estudo. As mais elevadas 
concentrações mínimas inibitórias foram de 64 mg/L para o cloreto de benzalcónio e de  
512 mg/L para o hipoclorito de sódio. É relevante mencionar que as estirpes com origem em 
produtos prontos a cozinhar estudadas, apresentavam-se totalmente resistentes à actividade 
do hipoclorito de sódio. 
 
Relativamente ao funcionamento da bomba de efluxo e à actividade do respectivo inibidor foi 
possível constatar que tipicamente a presença do inibidor devolvia inteiramente, até a 
concentração máxima de 40 mg/L, a susceptibilidade à ciprofloxacina. Para as estirpes 
classificadas como HLR, no entanto, a resistência a ciprofloxacina persistiu mesmo perante a 
concentração de inibidor mais alta testada: 120 mg/L.  
 
È actualmente inquestionável a necessidade crescente de melhor compreender o processo 
subjacente ao desenvolvimento de resistências a antimicrobianos. O uso inadequado destes 
compostos levou ao aparecimento disseminado de estirpes resistentes associado a padrões de 
resistencia múltipla indicando a rápida perda de eficácia dos agentes actualmente disponíveis 
no tratamento de infecções em humanos. A necessária introdução de mecanismos de 
regulação e controlo deverá ser feita paralelamente à combinação de informações 
epidemiológicas disponíveis num contexto mundial em que Portugal não será a excepção. 
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1. Introduction 
1.1. General considerations 
Thermotolerant Campylobacter spp., especially Campylobacter jejuni and Campylobacter coli, 
are considered to be the most frequent causative agents of human bacterial enteritis worldwide 
(Možina et al., 2011), even though, according to the European Food Safety Authority (EFSA) 
the reported cases of human campylobacteriosis represent only a small fraction of the actual 
number that occur (Butzler et al., 2004; EFSA Journal, 2010). Campylobacter is also recognized 
as a major contributing factor to Guillain-Barré syndrome, the most common cause of acute 
paralysis in both children and adults (Mena et al., 2008). 
 
Poultry meat is acknowledged as one of the most relevant food-borne sources of 
Campylobacter spp. human infection. The occurrence of this bacterium along the food 
processing chain, from flocks to processed poultry products sold to the consumers, is now the 
spotlight for applying control measures in order to restrict, as much as possible, the contact 
between human and Campylobacter spp. (Hermans et al., 2011). 
 
Typically the clinical syndrome associated with campylobacter infection resolves itself in a timely 
manner (Moore et al., 2006). Still, on occasion, drug therapy is required. Macrolides, namely 
erythromycin and fluoroquinolones, such as ciprofloxacin are currently the main prescribed 
antimicrobial agents. The ever growing resistance patterns reported for such compounds as 
well as for cleaning and disinfection compounds used daily along the food processing chain is 
an alarming public health issue (Skirrow et al., 2000; Moore et al., 2006; Možina et al., 2011).  
 
Vicente et al. (2008) searched the PubMed database for the keywords Campylobacter and 
Portugal retrieving a mere seven publications, of which only one, published in 1992, reported 
results collected at the national level. Since then, several more articles have already been 
published concerning human Campylobacter infections in Portugal. 
 
The purpose of this work was the phenotypic and genotypic characterization of isolates from 
different origins: extensive indoor, organic and intensive production systems, human stool 
samples from patients with campylobacteriosis and retail processed poultry products, in order to 
perceive the general panorama regarding antimicrobial resistance patterns for both poultry and 
human strains in Portugal. 
 
1.2. The genus Campylobacter 
In 1886, Theodor Escherich observed microorganisms in stool samples from children with 
diarrhea that morphologically resembled campylobacters. Later McFaydean and Stockman 
(1913) identified Campylobacter-like bacteria from fetal tissues in aborted sheep. Still, it was not 
until the 1970’s, with the development of an appropriate selective growth media and the 
isolation of campylobacters from stool samples of patients with diarrhea, that  
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Campylobacter spp. became, at last, widely recognized as a human pathogen  
(Skirrow et al., 1977; Altekruse et al., 1999; Hänninen et al., 2010). Campylobacter is now 
acknowledged as one of the most important causes of bacterial gastrointestinal infection in 
humans (Peterson et al., 1994). 
 
Campylobacter (from the Greek campylo, "curved" and bacter, "rod") belongs to the epsilon 
class of Proteobacteria, order Campylobacteriales. This order includes two other genera: 
Helicobacter and Wolinella. Like Campylobacter, members of this genus have relatively small 
genomes (1.6 to 2.0 mega bases) and can establish long-term associations with their hosts, 
sometimes with pathogenic consequences. The genus Helicobacter includes the specie  
H. pylori which, although able to be asymptomatically carried for decades, can cause gastric 
ulcers in humans and is therefore considered a pathogen. The genus Wolinella includes a 
single species, W. succinogenes, which colonizes cattle as a commensal organism  
(Young et al., 2007).  
 
Thirty two Campylobacter species have currently been described  
(Euzéby LBSN, http://www.bacterio.cict.fr/, accessed September 2011). Campylobacter spp. 
have been isolated from a large variety of different animals, and each Campylobacter species 
seems to favor certain animal species. Typically, members of the Campylobactereacea family 
are gram-negative, slender and spirally curved rods, small in size (0.2 – 0.5 µm) with a 
characteristic corckscrew-like darting motility by means of a single polar flagellum located at one 
or at both ends of the bacteria. They generally require low oxygen concentrations (3 to 15%) 
and carbon dioxide concentrations of 3 to 5%, hence being microaerophilic. Campylobacter spp. 
are fastidious organisms requiring complex growth media and are unable to ferment or oxidize 
carbohydrates, with the exception of L-fucose (Peterson et al., 1994, Vliet & Ketley, 2001; 
Debruyne et al., 2008; Stahl et al., 2010). 
 
The most important Campylobacter species are C. jejuni, accounting for over 90% of infections, 
and C. coli accounting for most of the remaining infections (Gibreel et al., 2006). Growth 
temperature ranges from 34 to 44°C, with an optimal temperature of 42°C. This probably 
reflects the species adaptation to the intestines of warm-blooded animals, namely birds, which 
are the most frequent natural reservoirs. Natural reservoirs include both wild animals, namely 
migratory birds or rodents, and domestic animals such as poultry, pigs, ruminants, cats and 
dogs. These bacteria can also be found in natural water sources as well as in foodstuffs 
typically of animal origin, implicating poultry meat and raw milk as major sources of human 
infection (Vliet and Ketly, 2001). Cross contamination to vegetables has been described (Kumar 
et al., 2000). Seldomly, humans can also transmit the disease to other humans by fecal-oral 
route (Altekruse et al., 1999; Young et al., 2007). Eating or handling undercooked chicken meat 
is considered one of the most important risk factors for human infection with reports stating that 
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up to 90-100% of retail chicken meat world-wide is contaminated with Campylobacter spp. 
(Butzler et al., 2004; Olson et al., 2008; Možina et al., 2011).  
 
1.3. Epidemiological studies, Campylobacter jejuni and Campylobacter coli. 
Epidemiological studies of Campylobacter infections indicate that there are two disease 
manifestations which are dependent on socio-economic status. In industrialized countries the 
incidence of C.jejuni/C. coli peaks during infancy and again in young adults aging from  
15 – 44 years contributing primarily to morbidity (Butzler et al., 2004). In the developing 
countries, children under the age of 5 are predominately affected but, severe manifestations of 
the infection are uncommon and isolation of C. jejuni, both from children with diarrhea as from 
those who are healthy, is extremely frequent (Blaser et al., 1985; Young et al., 2007).  
 
The European Food Safety Authority and the European Centre for Disease Prevention and 
Control has analyzed the information on the occurrence of zoonoses and food-borne outbreaks 
in 2009, submitted by 27 European Union Member States (EU-MSs). Campylobacteriosis was 
the most commonly reported zoonosis, since 2005, with 198252 human cases. Reported 
campylobacteriosis case fatality rate was 0.02%, which is still lower than for salmonellosis. It is 
worth mentioning the absence of results concerning campylobacteriosis cases in humans for 
both Portugal and Greece (Table 1). 
 
Seasonality has also been associated to the occurrence of campylobacteriosis. The highest 
numbers and notification rates of Campylobacter cases in humans were reported during the 
summer months, from June to August, and start gradually decreasing from September to 
December (EFSA Journal, 2011). 
 
Antimicrobial resistance patterns have been previously described. An inevitable side effect of 
the use of antibiotics is the emergence and dissemination of resistant bacteria and resistance 
genes. Resistant bacteria from animals can infect the human population not only by direct 
contact but also via food products of animal origin (Fàbrega et al., 2008). Table 2 resumes the 
general panorama regarding ciprofloxacin and erythromycin resistance regarding several 
european countries. 
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Table 1 - Reported campylobacteriosis cases in humans 2005-2009 and notification rates for 2009. EFSA- 
EU summary report on trends and sources of zoonoses and zoonotic agents and food-borne outbreaks 
2009, Published 22nd March 2011. 
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Table 2 -  General panorama regarding  Campylobacter jejuni and/or Campylobacter coli resistance to ciprofloxacin and erythromycin for some relevant european countries. 
CIP, ciprofloxacin; ERY, erythromycin. 
 
 
  
Country Strain origin 
Tested 
strains 
Campylobacter spp. C.jejuni C.coli 
Ref. 
CIP ERY CIP ERY CIP ERY 
France Human / broiler 1135 - - 25.3%/ 9.4% 1.4%/ 0% 42%/ 32.4% 12.5%/ 17.6% Gallay et al., 2007 
Switzerland Poultry (retail raw meat) 91 28.7% 1.1% - - - - Lederberger et al., 2003 
Slovenia Poultry (retail raw meat) 55 58.2% 14.5% - - - - Kurinčič et al., 2005 
Finland Human 226 59.3% - - - - - Lehtopolku et al., 2005 
Portugal Poultry retail meat 99 90% 90% - - - - Mena et al., 2008 
Portugal Human 123 80.5% - - - - - Vicente et al., 2008 
Denmark Human / broiler 93 - - 24%/ 0% 0%/ 0% - - Danmap et al., 2009 
Italy Human / broiler 309 - - 38.2%/ 42.2% 1.4%/ 3.1% 55.2%/ 75% 24.1%/ 45% Pezzotti et al., 2003 
Spain Human / broiler 754 - - 75%/ 98.7% 3.2%/ 20.3% 70.7%/ 100% 34.5%/ 90% Saenz et at., 2000 
Germany Human / broiler 509 - - 46.2%/ 42% 0%/ 0.8% 41.2%/ 70.6% 29.4%/ 5.9% Luber et al., 2003 
Sweden Human / broiler 208 6% / 2% 0% / 0% - - - - Rönner et al., 2004 
Ireland Human / Chicken 377 17.4%/ 4.5% 4.2%/ 11.4% - - - - Moore et al., 2001 
6 
 
Table 3 - Clinical features of Campylobacter 
enteritis derived from surveys of community 
outbreaks in which or more people were affected 
and analyzed. (Skirrow et al., 2000). 
Symptom 
Frequency (%) 
Mean/median Range 
Fever (25) 50/52 6-75 
Diarrhea (26) 84/85 52-100 
Headache (21) 41/47 6-69 
Abdominal pain (26) 79/80 56-99 
Myalgia (5) 42/37 28-59 
Vomiting (20) 15/11 1-42 
Blood in feces (7) 17/13 0,5-32 
 
1.4. Pathology and disease 
Many questions are still open concerning campylobacters pathogenic mechanisms but many 
have already been understood. To establish an infection, as other pathogenic bacteria, C. jejuni, 
in association with food or water must bypass both mechanical and immunological barriers of 
the gastrointestinal tract in order to enter the host intestine, via the stomach acid barrier, and 
colonize the distal ileum and colon. Following colonization of the mucus and adhesion to 
intestinal cell surfaces, campylobacters perturb the normal absorptive capacity of the intestine 
by damaging epithelial cell function either directly, by cell invasion or toxin(s) production, or 
indirectly, by initiating an inflammatory response. As these possible mechanisms are not 
mutually exclusive, any combination may have a role depending on the host status and 
attributes of the infecting strain (Ketley, 1997). 
 
Campylobacter enteritis is an acute diarrheal disease with clinical manifestations like those of 
other bacterial gut infections that distress the intestinal tract, such as salmonellosis or 
shigellosis. Except for the fact that in humans, C. jejuni is responsible for the great majority of 
enteric Campylobacter infections (80–90%), leaving C. coli responsible for most of the 
remaining 10 to 20% which can also be ascribed, in a lower proportion, to C. lari and 
C. upsaliensis.There does not seem to be any greater differences between the clinical outcome 
of infections caused by either C.jejuni or C. coli (Fitzgerald et al., 2008). 
 
Generally, the infective Campylobacter dose is low. Infection has been induced with doses as 
low as 500 bacteria and this number may even be lower when milk or water-borne 
contamination occurs due to the buffering and/or "wash-through" effect throughout the stomach 
contents. The incubation period ranges from 18h to 8 days being 3.2 days the average 
incubation period (Skirrow et al., 2000). 
 
The clinical outcome of Campylobacter 
contamination is determined by the 
virulence of the infecting strain, the 
challenge dose and also on the patients 
susceptibility (health status, age). The onset 
of the disease is often abrupt starting with 
severe abdominal pain followed by profuse, 
watery, bile stained and sometimes 
prostrating diarrhea. Blood in stool may 
occur as infection progresses into the colon 
and rectum (Table 3). Severe symptoms do 
regress after 3 to 4 days into the illness but 
patients continue to excrete campylobacters 
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in their faeces for several weeks after they have clinically recovered, unless the antibiotic 
treatment took place (Skirrow et al., 2000).  
 
Generally, the illness is self-limiting completing resolving itself in a timely manner. Although less 
frequently, Campylobacter infection may produce other, more severe outcomes, resulting in 
severe intestinal compromise or even extraintestinal complications such as bacteremia, septic 
arthritis, Reiter’s syndrome or Guillian-Barré syndrome (GBS), amongst others. The latter is the 
most serious post-Campylobacter infection complication, occurring in 1 out of every  
1000 campylobacteriosis affected individuals with symptoms beginning 1 to 3 weeks after the 
onset of Campylobacter enteritis. Campylobacter associated GBS cases results in a usually 
severe disorder of the peripheral nervous system characterized by ascending symmetrical 
weakness and eventually paralysis requiring intensive hospital treatment with a possibility of 
long-term disability or even a fatal outcome. Although not well defined, some investigators have 
reported that GBS following Campylobacter infection may be more severe and result in more 
irreversible neurologic damage than GBS following other putative infections  
(Nachamkin et al., 1998). The autoimmune response underlying GBS owes itself to the 
occurrence of molecular mimicry between various C. jejuni LOS (lipooligosaccharide) structures 
and human neuronal gangliosides (Nachamkin et al., 1998).  
 
Still, having in general a very good prognosis, no specific treatment is required for the majority 
of patients with Campylobacter enteritis other than supportive measures such as fluid and 
electrolyte replacement. Antibiotic therapy is only advised for patients acutely ill with enteritis, 
persistent fever or suffering from either prolonged or bloody diarrhea. HIV (human 
immunodeficiency virus) positive or other immunocompromised individuals should initiate 
antibiotic treatment as soon as possible for the outcome, when therapy is delayed, may not turn 
out to be as successful (Altekruse et al., 1999; Skirrow et al., 2000)  
 
1.5. Antibiotic therapy: Selected antibiotics for campylobacteriosis 
management 
The introduction of antibiotics was one of the most important medical interventions regarding 
the reduction of human morbidity and mortality. The discovery of penicillin in 1928 by Alexander 
Fleming was the beginning of modern antibiotic medicine. Mass production started in the 1940s, 
and today hundreds of antimicrobials are available on the market. An estimated half of the 
globally produced antimicrobials are used for food animals (World Health Organization, 2009).  
 
Antibiotics can be classified based on the cellular component or system they affect in addition to 
whether they induce cell death (bactericidal effect), or merely inhibit cell growth (bacteriostatic 
effect). Most bactericidal antimicrobials act by inhibiting DNA, RNA, cell wall or protein synthesis 
(Kohanski et al., 2010). They can be synthetic or semi-synthetic compounds or natural 
substances produced by other microorganisms.  
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The intensive use of antibiotics since the 1940s, has dramatically increased the frequency of 
resistance among human pathogens and threatens a loss of therapeutic options and an 
upsurge of a post-antibiotic era in which the medical advances to date are negated. Resistance 
dramatically reduces the possibility of treating infections effectively and increases the risk of 
complications and of a fatal conclusion. Every year in the European Union alone it is estimated 
that over 25000 people die of antibiotic-resistant bacterial infections, mostly acquired in 
hospitals (Andersson & Hughes, 2010; World Health Organization, 2011). 
 
As previously mentioned, most cases of enteritis do not require treatment as they are of short 
duration, clinically mild and self limiting. However, antimicrobial therapy is imperative when long-
lasting infections and/or systemic compromise after Campylobacter infections occur or when 
infection arises in immune-suppressed patients. Two major classes of antibiotics are taken 
under consideration regarding the treatment of Campylobacter induced infection. The macrolide 
Erythromycin is considered the drug of choice for treating Campylobacter gastroenteritis and 
ciprofloxacin and tetracycline are used as alternative drugs. Eventually aminoglycosides such 
as gentamicin can be used for serious systemic infections (Skirrow et al., 2000;  
Alonso et al., 2005; Gibreel et al., 2006) 
 
1.5.1. Macrolides: Erythromycin 
The term “macrolide” is used to describe drugs with a macrocyclic lactone ring of 12 or more 
elements. This class of compounds includes a variety of bioactive agents, including antibiotics. 
The 14-, 15-, and 16-membered macrolides are a widely used family of antibiotics  
(Ladely et al., 2009). They have excellent tissue penetration and antimicrobial activity, mainly 
against Gram-positive cocci and atypical pathogens. The macrolide antibiotics include natural 
members, prodrugs and semi-synthetic derivatives. Erythromycin A, a 14-membered macrolide, 
was isolated from cultures of Streptomyces erythreus and was the first macrolide introduced into 
clinical practice, being approved by the FDA in 1959 (Piretti et al., 1992). Later on, in 1991, 
azythromycin was FDA approved. This semi-synthetic macrolide is similar in structure to 
erythromycin but has a better farmacokinetic proprieties than the latter, considering oral 
bioavailability,  tissue penetration and persistence, and long elimination half-lives, which allow 
for once-daily or twice-daily dosing however, azithromycin does not exhibit increased potency in 
comparison with erythromycin (Piscitelli et al., 1992; Gibreel et al., 2007).  
 
Erythromycin is a bacteriostatic agent that acts as a protein synthesis inhibitor  
(Taylor & Tracz, 1991). Erythromycin attaches itself, through hydrogen bonds between the 
macrolide desosamine sugar group and the polar groups on specific nucleotides: 2058 and 
2059 (Escherichia coli numbering) causing the dissociation of the peptidyl-tRNA in the 50S 
tunnel where elongation takes place (Figure 1) (Engberg et al., 2001, Ladely et al., 2009). The 
occurrence of point mutations within the peptidyl-transferase region, in domain V of the 23S 
rRNA target gene, which is the main anchoring point for macrolides, prevents erythromycin from 
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Figure 1 - Secondary structure of the peptidyl-
transferase loop in domain V of C. jejuni/coli 23S 
rRNA. Positions 2058 and 2059 (based on E. coli 
numbering) refer to the location of the mutations 
associated with erythromycin resistance, 
corresponding to positions 2074 and 2075 for C. 
jeuni. From Gibreel & Taylor, 2006.  
attaching. In the majority of macrolide-
resistant C. jejuni isolates, the resistance-
associated mutations were identified in the 
three chromosomal copies of the target gene, 
however no correlation was observed 
between the level of macrolide resistance in 
Campylobacter isolates and the number of 
mutated copies of the 23S rRNA gene 
(Gibreel & Taylor, 2006; Ladely et al., 2009). 
Still, at least two mutated copies are 
necessary to confer macrolide resistance and 
both the wild-type and mutated alleles can 
coexist in a single macrolide-resistant mutant 
(Gibreel & Taylor, 2006; Hao et al., 2009). So 
far, described point mutations occur at 
positions 2074 and 2075 of the 23S rRNA. The latter, an A→G transition, is the most frequently 
observed. This point mutation is usually associated with high-level erythromycin resistance 
phenotypic expression. Mutations occurring in position 2074, include the transition, A→G which 
is rare and somewhat unstable (Gibreel & Taylor, 2006). And the transversion, A→C, which is 
not only correlated with stable and high-level macrolide resistance, having even higher 
erythromycin minimum inhibitory concentrations than isolates with the A2075G transition, but 
also associated with a fitness cost (Hao et al., 2009). A recent finding demonstrated that 
modifications in the ribosomal proteins L4 (V4E and V196A) and L22 (G86E) (insertions at 
position 86 or 98) also conferred macrolide resistance in Campylobacter (Hao et al., 2009). 
 
1.5.2. Fluoroquinolones: Ciprofloxacin 
Unlike some of the first discovered antibiotics, the quinolone class of antimicrobial agents was 
not isolated from living organisms but, rather synthesized by chemists. Nalidixic acid, a by-
product of the synthesis of the antimalarial compound chloroquine was accidentally discovered 
in 1962 by Leser and his collegues and introduced in the same decade to treat urinary tract 
infections. Nalidixic acid and other first generation quinolones are rarely used today due to their 
toxicity. Second (ciprofloxacin), third (levofloxacin) and fourth (gemifloxacin) generation 
quinolone antibiotics can be classified on the basis of their chemical structure and of qualitative 
differences between the killing mechanisms they use. (Andriole, 2005; Kohanski et al., 2010). 
 
Quinolones are classified as nucleic acid inhibitors due to their interference with the modulation 
of chromosomal supercoiling by meddling with the topoisomerase-catalysed strand breakage 
and rejoining reactions. DNA gyrase induces negative supercoils in the DNA while 
topoisomerase IV is important in unlinking activity, making both enzymes essential. Thus 
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cessation of their activities results in cessation of bacterial growth and death  
(Kohanski et al.,2010). 
 
Fluoroquinolone resistance in Campylobacter spp. appears to be due to the occurrence of 
mutations in the genes encoding subunits of DNA gyrase. The GyrA and GyrB subunits of DNA 
gyrase are respectively homologous with the ParC and ParE subunits of topoisomerase IV 
although Campylobacter, as well as other microorganisms such as Helicobacter pylori and 
Mycobacterium tuberculosis, do not have topoisomerase IV (Engberg et al., 2001;  
Fàbrega et al., 2008). Cloning and sequencing of C. jejuni gyrA gene demonstrated that 
mutations in gyrA at positions Thr-86, Asp-90, Ala-70 and Pro-104 were responsible for 
fluoroquinolone resistance. The first mentioned is associated with higher level resistance to 
nalidixic acid and ciprofloxacin than the alternative mutations (Table 4) (Engberg et al., 2001).  
 
Table 4 - Fluoroquinolone resistance mechanisms reported in Campylobacter species (Adapted from 
Engberg et al., 2001). 
Fluoroquinolones  gyrA Thr-86 (Higher MIC to fluoroquinolones) 
   Asp-90, Ala-70 and Pro-104 (Lower MIC to fluoroquinolones ) 
 
 
1.5.3. Tetracyclines: Tetracycline 
The tetracyclines, which were discovered in the 1940s, are a family of antibiotics that inhibit 
protein synthesis by preventing protein translation by inhibiting the aminoacyl-tRNA binding to 
the ribosome (Chopra & Roberts, 2001; Kohanski et al., 2010). Tetracyclines are  
broad-spectrum agents with no major adverse side effects which has led to the extensive use in 
therapy of both human and animal infections (Chopra & Roberts, 2001). Tetracycline high-level 
resistance is primarly mediated by the plasmid encoded gene, tet(O), which encodes for the 
ribossomal protection protein Tet(O). This protein is structurally related to the translation 
ribossome-binding proteins, and acts by displacing tetracycline from its primary binding site on 
the ribossome (Chopra & Roberts, 2001; Pratt & Korolik, 2005).  
 
1.5.4. Aminoglycosides: Gentamicin 
Aminoglycosides are highly potent, broad-spectrum antibiotics. In 1944 streptomycin was the 
first to be attained, followed by other relevant compounds such as kanamycin, gentamicin, and 
tobramycin which definitively established the usefulness of this class of antibiotics for the 
treatment of gram-negative bacillary infections (Mingeot-Leclercq et al., 1999). 
 
Aminoglycosides act primarily by impairing bacterial protein synthesis through binding to 
prokaryotic ribosomes, namely the 16S rRNA component of the 30S ribosome subunit  
(Mingeot-Leclercq et al., 1999; Kohanski et al., 2010). Passage of these highly polar molecules 
across the outer membrane of gram-negative bacteria typically involves the drug-induced 
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disruption of Mg2+ bridges between adjacent lipopolysaccharides and the subsequent transport 
of aminoglycosides across the cytoplasmic membrane which is dependent of electron transport. 
Upon reaching the cytosol aminoglycosides perturb the elongation of the nascent chain by 
impairing the proofreading process controlling translational accuracy (misreading and/or 
premature termination). The aberrant proteins may be inserted into the cell membrane, leading 
to altered permeability and further stimulation of aminoglycoside transport  
(Mingeot-Leclercq et al., 1999). 
 
1.6. The efflux pump – efflux pump inhibitors 
Efflux pumps are transport proteins involved in the extrusion of toxic substances from within 
cells into the external environment. These pumps may be specific for one substrate or may 
transport a relatively wide range of structurally dissimilar compounds, including antibiotics of 
different classes. In gram-negative bacteria three mechanisms of resistance have been 
described which include drug inactivation, active efflux and modification of the target sites by 
methylation or mutation. Until recently little was known about efflux systems in Campylobacter 
spp., the first approach on the subject was made by Charvalos et al. (1995) who pinpointed the 
existence and contribution to multidrug resistance of a promiscuous efflux system  
(Lin et al., 2002).  
 
In the prokaryotic kingdom there are five major families of efflux transporters: MF (major 
facilitator), MATE (multidrug and toxic efflux), RND (resistance-nodulation-division), SMR (small 
multidrug resistance) and ABC (ATP binding cassette) (Figure 2). All these systems utilize the 
proton motive force as an energy source apart from the ABC family, which utilizes ATP 
hydrolysis to drive the exportation of substrates (Webber & Piddock, 2003; Piddock, 2006).  
 
 
Figure 2 -. Diagrammatic representation of the five structural classes of bacterial efflux pumps. ABC: ATB 
binding cassettes, MFS: major facilitator superfamily, RND: resistance-nodulation-division, SMR: small 
multidrug resistance, MATE: multidrug and toxic compound extrusion, OM: outer membrane, P: periplasm, 
CM: cytoplasmic membrane, MFP: membrane fusion protein. (Adapted from Zechini & Versace, 2009). 
 
One important family of drug transporters in Campylobacter spp. are the resistance nodulation 
cell division (RND) efflux systems. Genetically, many of the RND-type efflux systems or pumps 
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are encoded by a three-gene operon located at the bacterial chromosome and the expression of 
these pumps is controlled by regulatory proteins. The efflux pump identified for  
Campylobacter spp. follows such expected conditions. CmeABC is a tripartite efflux system 
consisting of a periplasmic fusion protein (CmeA), an inner membrane drug transporter (CmeB) 
and an outer membrane protein (CmeC). CmeR is a transcriptional repressor that controls the 
expression of the mentioned pump and is encoded by a gene located immediately upstream of 
CmeABC. CmeR binds to the inverted repeat in the promoter region of CmeABC and inhibits 
the expression of the efflux operon (Akiba et al., 2006). 
 
CmeABC is essential for Campylobacter colonization in vivo by mediating resistance to bile 
salts normally present in the intestinal tract of animals. Besides bile salts, the pump allows the 
extrusion of a wide variety of compounds from dyes, heavy metals, detergents and antibiotics of 
different families thus contributing to multidrug resistance. In gram-negative bacteria, 
chromosomally encoded efflux pumps contribute to intrinsic resistance to a variety of 
antimicrobial agents, including macrolides, contributing to low level resistance. And although 
high levels of resistance may not occur as a result of MDR efflux pumps, the multidrug efflux 
pump works synergistically with other non-efflux resistance mechanisms such as target 
mutations to confer high levels of antimicrobial resistance in bacteria (Lin et al., 2002;  
Webber & Piddock, 2003; Mamelli et al., 2005; Akiba et al., 2006). In addition to CmeABC, 
Campylobacter spp. possesses another RND-type efflux pump CmeDEF, in which CmeD, 
CmeE and CmeF are predicted to be an outer membrane channel protein, a periplasmic fusion 
protein and inner membrane transporter, respectively. CmeDEF is expressed in low levels and 
acts interactively with CmeABC in conferring resistance to antimicrobials and toxic compounds 
(Akiba et al., 2006) 
 
1.7. Antibiotic growth promoters and antibiotic resistance 
The growth promoter effect of antibiotics was discovered in the 1940s, when it was observed 
that animals fed with dried mycelia of Streptomyces aureofaciens, containing chlortetracycline 
residues, had growth improvements (Castanon, 2007). Antibiotics are used in veterinary 
medicine for treatment and prevention of infections and as growth promoters in food animals.  
The term "antibiotic growth promoter" or AGP is used to describe any medicine that destroys or 
inhibits bacteria and is administered at a low, sub- therapeutic dose in order to help growing 
animals digest their food more efficiently, without the lost of energy diverted for microbial 
fermentation and thus getting the maximum benefit from it allowing for a faster development into 
strong and healthy individuals. If the microbial population is better controlled, it is possible that 
the lost energy could be diverted to the animal growth (NOAH, 2001; Hughes & Heritage, 2002; 
Soulsby, 2007).  
 
Early concerns about the impact of extensive utilization of AGPs could have on human health 
appeared in 1951 but it was not until 1969 that recommendations to ban the subtherapeutic use 
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of human medicine antibiotics in animal feeds were discussed. The first nation to eliminate the 
use of antimicrobials for growth promotion was Sweden in 1986. In 1997 avoparicin, a 
glycopeptide growth promoter was banned due to reports on glycopeptide- resistant enterococci 
(GRE) isolated from food animals in England. Although no connection was made between the 
resistance in bacteria from food animals and infection in humans, the concern that its use 
created an animal reservoir of GRE and that this was a potential risk to public health remained. 
Two years later, other individual growth promoters were banned by the EU Commission 
because they belonged to classes of antimicrobials also used in humans (tylosin, spiramycin, 
bacitracin, and virginiamycin) or were considered unacceptable due to occupational toxicity 
risks (olaquindox and carbadox). Denmark has restricted the use of antimicrobials to therapeutic 
use, by prescription only, since January 2000.  
 
European Regulation Concerning Additives in Animal Feeds Council published the  
70/524 directive, in the Official Journal L270 of December 14, 1970, the basic principle of this 
regulation was that only those additives which are named in the Directive may be contained in 
foodstuffs. The member states, brought into force the laws, regulations, and administrative 
provisions necessary to comply with this Directive within 2 years following the notification. 
Directive 70/524 was later replaced by Regulation 1831/2003 of the European Parliament and 
of the Council on additives for use in animal nutrition. This Regulation stated that antibiotics, 
other than coccidiostats and histomonostats (antiprotozoan agents), might be marketed and 
used as feed additives only until December 31, 2005. Anticoccidial substances, such as 
antibiotics ionophores, also will be prohibited as feed additives before 2013. After this date, 
medical substances in animal feeds will be limited to therapeutic use by veterinary prescription 
(Castanon, 2007). 
 
1.8. Disinfectants 
Although highly fastidious and stress-sensitive organisms, Campylobacter is able to survive in 
the slaughterhouse environment overcoming cleaning procedures. During slaughter in 
slaughterhouses the contents of the birds GI tract may spill during evisceration contaminating 
the carcasses. Although little information is available about Campylobacter susceptibility to 
disinfectants, it is generally considered susceptible to the disinfectants used in the food industry. 
Yet, the concern that the increasing use of chemical disinfection, particularly of quaternary 
ammonium and chlorine compounds, might contribute to the emergence of disinfectant-resistant 
microorganisms and the simultaneous cross-selection for antibiotic resistant of the same strains 
has been mentioned representing a public health burden (Moore et al., 2006;  
Peyrat et al., 2008). 
 
Typically, cleaning and disinfection, C&D, procedures are relatively standardized and performed 
daily. They start in all cases with removal of the organic matter with high-pressure water, then 
application of detergent and disinfectant molecules to surfaces presumed free of organic matter. 
14 
 
Campylobacter is usually considered susceptible to the disinfectant molecules used in the food 
industry still this bacterium is still routinely detected in floor surface swabs of commercial 
transport cages after C&D (Peyrat et al., 2007; Peyrat et al., 2008). The frequency of strains 
with a low-level resistance to quaternary ammonium compounds (QAC) is relatively high for 
other foodborne pathogens such as Listeria monocytogenes (10%), Staphylococcus aureus 
(13%) or spoilage bacteria such as Pseudomonas spp. (30%) isolated from food and food 
processing industry. In general, works performed in other bacteria led to the conclusion that 
bacteria isolated after disinfection are more resistant although no link between resistance to 
disinfectants and antibiotics has been observed for Campylobacter. Yet, a genetic linkage has 
been found between resistance to QAC and antibiotics in food associated Staphylococci, and 
there is a growing concern about cross-resistance between antibiotics and disinfectants  
(Moore et al., 2008). There is therefore a pressing need of developing more efficient C&D 
strategies and a better understanding of the mechanisms underlying the survival and resistance 
of Campylobacter in the environment limiting the public health burden the situation imposes 
(Peyrat et al., 2007; Peyrat et al., 2008). 
1.9. Poultry – production systems 
Poultry farming is the practice of raising poultry, such as chickens, turkeys, ducks and geese for 
the purpose of farming meat or eggs for human consumption. Broilers, chickens farmed for 
meat purposes, are generally held in large groups either in environmentally controlled housing 
or in open, naturally ventilated poultry houses. Broilers are usually kept free on deep litter with 
automated provision of feed and water. In most countries, commercial breeds selected for rapid 
growth, are used. Farmers around the world understand that in order to raise the birds with 
maximum efficiency, many conditions must be fulfilled – stress prevention, supply of good feed 
and water, and good sanitation. In providing these conditions, farmers ensure a basic level of 
animal welfare (Horne & Achterbosch, 2008).  
 
Several farming techniques are currently used for poultry production: organic, extensive indoor 
and intensive production system. Organic production systems require a maximum of 10 birds 
per m2 with mandatory access to access an outdoor range (4 m2/bird), organic feeding is 
required. Organic chickens are slow growers; more traditional breeds are used and live typically 
for around 81 days till slaughter. Extensive indoor production systems imply that 12-14 birds are 
maintained per m2, poultry are raised on pasture, enabling the poultry to move around and 
forage for their natural diet. Extensive indoor production allows broilers to live typically for  
56- 81 days before slaughter. Meat chickens subjected to intensive production system are floor-
raised on litter such as wood shavings or rice hulls, and kept indoors in climate-controlled 
housing. Poultry producers routinely use legally approved medications, in feed or drinking 
water, to treat disease or to prevent disease outbreaks, no outdoor access is required and 
animals will live less than six weeks before slaughter (Fuller, 2004). 
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1.10. Aims of the study 
Given the general panorama regarding the occurrence of Campylobacter, namely 
Campylobacter jejuni and Campylobacter coli, along the food processing chain, from broiler 
flocks till processed retail products, and the human health consequences such a situation 
imposes the need to make notification mandatory. Not only due to its prevalence, but also due 
to the ever growing levels of resistance reported for Campylobacter in paralel with scarce 
results and notification rates that Portugal currently possesses for both foodstuffs and more 
importantly in humans. It was only relevant to adress the matter at hand by providing a new set 
of results regarding antibiotic and biocide resistance for C.jejuni and C. coli from human and 
broiler origin.  
 
The purpose was this study was to performe susceptibility testing, using 7 different classes of 
antibiotics, for target isolates in order to understand the general panorama concerning resistant 
profiles showed by the tested strains as representative strains and then to select those that 
showed a multiple resistant profile. Selected strains were then re-tested for antibiotic and 
disinfectant resistant patterns and for the detection of point mutations to with resistance is highly 
attributed. The effect of an efflux pump inhibitor, to which restored susceptibility has been 
described was also studied.  
 
2. Materials and Methods 
2.1. Campylobacter isolates collection 
The Campylobacter isolates (N = 258) used in the present study belonged to the collection of 
the Laboratório de Tecnologia e Segurança dos Alimentos at the Faculdade de Medicina 
Veterinária da Universidade Técnica de Lisboa. Isolates were attained from samples of different 
origins: 
 
a.  Caecum, carcass (neck skin) and breast meat were sampled at a poultry 
slaughterhouse, considering flocks’ traceability for organic, extensive indoor and 
intensive production system in different days in 2008.  
b. Retail samples of different processed poultry products, ready to cook and packaged 
under modified atmosphere/MAP (poultry deboned pieces, steaks, fresh sausages, 
burgers, balls, stroganoff, hot wings, marinated poultry meat and seasoned poultry 
meat) from different industrial units, were collected from October to December 2009,  
c. Human campylobacter isolates, kindly provided by the Instituto Nacional Saúde Dr. 
Ricardo Jorge, were attained from patients with campylobacteriosis during 2008 and 
2009. Strains from human origin were thus received isolated and purified in Columbia 
blood agar plates adequately prepared for transportation between institutions. 
 
16 
 
2.2. Campylobacter isolation and identification. 
Campylobacter isolation was performed according to ISO10272-1:2005. Presumptive genus 
identification of the isolates was performed by: colony observation, observation of cell 
morphology, Gram staining and catalase and oxidase production. Hipurate hydrolysis allowed 
for the initial differentiation between C. jejuni and C. non-jejuni strains. C. jejuni and C. coli 
identification was performed after DNA extraction (Quiagen Kit DNA extraction  
(Qiagen, Valencia, CA, USA) or Pitcher et al. (1999)), by multiplex-PCR according to  
Dennis et al., (1999) or for cdtA, cdtB and cdtC according to Samorsornsuk et al. (2007).  
 
2.3. Reference strains 
The reference strains C. jejuni K49/4 and ZIM 375/06, C. coli ZIM 140 were kindly provided by 
Prof. Sonja Možina from the University of Ljubljana, Lithuania. C. jejuni NCTC11168 was kindly 
provided by Prof. Naoaki Misawa from Japan. Staphylococcus aureus ATCC 25923 and 
Enterococcus faecalis ATCC 29212 belong to the Faculdade de Medicina Veterinaria collection 
and were used as disc susceptibility and minimum inhibitory concentration testing controls. 
 
2.4. Storage and preservation of bacterial strains 
Campylobacter isolates and reference strains were cryogenically preserved in Brain Hearth 
Infusion (Scharlau) with 30% glycerol (Scharlau) and were frozen at -80ºC  
(ThermoFisher Scientific, USA).  
 
2.5. Bacterial growth conditions 
Bacterial strains were grown on Columbia Blood agar (BioMerieux), supplemented with 5% 
horse blood and incubated at 42°C for 48h under microaerobic conditions  
(5% O2, 10% CO2 and 85% N2) in gas tight containers. 
 
2.6. Agar disc diffusion method 
The agar disc diffusion method is a widely used, fast and a relatively low-cost, method for 
screening antimicrobial susceptibility that provides results classifying isolates as resistant, 
intermediate or susceptible (Wiegand et al., 2008). For this test, an appropriate culture medium, 
Mueller-Hinton agar, was uniformly inoculated with the test organism. Filter paper discs, which 
impregnated with a specific concentration of a particular antibiotic, were placed on the 
medium.  The organism grew on the agar plate while the antibiotic potentially inhibits the 
growth. Disc diffusion susceptibility testing was performed according to Comité de 
l’antibiogramme de la Société Française de Microbiologie (CA-SFM) and European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) for eleven antibiotics of 7 different antibiotic 
classes (Table 5): Ampicilin (10µg); erythromicin (15 µg), tetracycline (30 µg);  
chloramphenicol (30 µg); gentamicin (10 µg); ciprofloxacin (5 µg), nalidixic acid (10 µg); 
norfloxacin (5 µg); ofloxacin (5 µg); amoxacilin + clavulanic acid (20 + 10 µg) and  trimethropim 
+ sulfametoxazole (25 µg). Strains were classified as resistant, intermediate or susceptible 
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according to CA-SFM, 2011. For intensive production poultry origin isolates disc diffusion 
testing was not performed because the data had already been published by Borges (2009). 
 
Table 5 - List of all antibiotics and respective concentrations used in agar disc diffusion susceptibility 
testing of all strains. 
Antibiotic type (class) Antibiotic agents Disk concentration Supplier 
β-lactam 
Ampicillin 10µg Liofilchem 
Amoxacilin + clavulanic acid 20 + 10µg Liofilchem 
Macrolide Erythromycin 15µg Liofilchem 
Tetracyclines Tetracycline 30µg Liofilchem 
Phenicols Chloramphenicol 30µg Liofilchem 
Aminoglycosides Gentamicin 10µg Liofilchem 
Fluoroquinolone 
Ciprofloxacin 5µg Liofilchem 
Nalidixic acid 10µg Liofilchem 
Norfloxacin 5µg Liofilchem 
Ofloxacin 5µg Liofilchem 
Trimethoprim/ 
sulfamethoxazole Trimethoprim/sulfamethoxazole 25µg Oxoid 
 
Quality control (QC) strains Staphylococcus aureus ATCC 25923 and Enterococcus faecalis 
ATCC 29212, for which quality control ranges have been established, were included in all 
studies (according to CLSI, 2008 - Clinical and Laboratory Standards Institute).  
 
All bacterial isolates were grown on Mueller-Hinton agar (Scharlau), supplemented with 5% 
horse or sheep blood (bioMérieux). After antibiotic disc distribution on plates, campylobacters 
isolates were incubated at 42°C for 48h under microaerobic conditions  
(5% O2, 10% CO2 and 85% N2) in gas tight containers while QC strains were incubated at 37ºC 
for 24h. 
 
2.7. Mutation detection for erythromycin resistance – RFLP-PCR 
Detection of the occurrence of the point mutation at position 2075 was done by RFLP-PCR, 
Restriction Fragment Lenght Polymorphism – Polymerase Chain Reaction. The  
Campylobacter strains ZIM K49/4, ZIM 140, ZIM 375-06 were used as controls (Table 6). E. coli 
CCUG 42744 was a used as a negative control strain. 
 
Table 6 - Control strains used in the detection of the point mutation A2075G 23S rRNA by RFLP-PCR. 
Control strain Species Origin Characteristics 
ZIM K49/4 C. jejuni Domestic birds, Slovenia Erythromycin susceptible (EryS) 
ZIM 140 C. coli Domestic birds, Slovenia Erythromycin resistant (EryR) 
ZIM 375-06 C. jejuni Human Erythromycin resistant (EryR) 
 
The methodology used was performed according to Leser et al. (1997) and Kurinčič et al. 
(2007) with modifications, and was the same for both C. jejuni and C. coli strains. A forward, 
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Ery23SFor (5′GTAAACGGCCGTAACTA3′) (Stabvida) and a reverse primer, Ery23SRev 
(5′GACCGAACTGTCTCACGACG3′) (Stabvida) were used to amplify a 714 bp long fragment. A 
mutation at position 2075 resulted in five fragments after BsmAI (Biolabs) digestion (DNA 
fragments attained: 311, 226, 102, 57 and 18 bp). The amplification was carried out in the 
following conditions: an initial denaturation step at 95ºC for 5 min, followed by 35 cycles of 
denaturation at 95ºC for 1min, annealing at 51.9ºC for 1min, and extension at 72ºC for 1min, 
and a final extension at 72ºC for 5 min, were performed using a Doppio thermocycler  
(VWR, Belgium). Digestion with BsmAI was performed for 1h at 50ºC. The fragments were 
separated at 50 volts for 1h (GelXL plus, Labnet) on 1.5% agarose (SeaKem) gel. 
 
2.8. Multiple resistant strain selection  
From the original 258 isolated, 14 strains of each production system poultry samples, 14 strains 
of human origin and 24 strains of retail origin were selected concerning their resistance to more 
than two antibiotic classes, preferably over 3 antibiotic classes (Table 7). Selection was 
performed mainly according to the previously attained results for disc diffusion susceptibility 
testing. Selected strains were screened for tetracycline, gentamicin, erythromycin and 
fluoroquinolone resistance by minimum inhibitory concentrations testing. The occurrence of 
point mutations potentially responsible for erythromycin and fluoroquinolone resistance, 
respectively were determined by MAMA-PCR. For intensive production poultry origin isolates 
the selection was based on previous results from Borges (2009). 
 
Table 7 - Comprehensive resume of all the isolates initially used concerning: Isolates origin, number of 
isolates for each origin (nA), species identification (ID), number of each species for each origin (nB) and 
number of multiple resistant strains (nC). 
 
2.9. Antimicrobial susceptibility testing: Minimum inhibitory concentrations 
Minimum inhibitory concentrations (MICs) are considered the "gold standard" for determining 
the susceptibility of organisms to antimicrobials and are therefore used to judge the 
performance of all other methods of susceptibility testing. MIC is defined as the lowest 
concentration of a drug that will inhibit the visible growth of an organism after incubation 
Strain origin nA  ID nB  nC 
Extensive indoor production system 
samples 40 
C. jejuni 22 8 
C. coli 18 6 
Organic production system samples 44 C. jejuni 27 3 C. coli 17 11 
Intensive production system 
samples 43 
C. jejuni 17 6 
C. coli 26 8 
Human patients samples 65 C. jejuni 45 8 C. coli 20 6 
Retail samples 66 C. jejuni 1 0 C. coli 65 24 
     
Totals N=258 C. jejuni 112 26 C. coli 146 54 
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(Andrews, 2006). MICs were performed on the previously selected strains for 4 different 
antibiotics: ciprofloxacin, erythromycin, tetracycline and gentamicin (Table 8).  
 
The choice of disinfectant molecules was limited to chloride and quaternary ammonium 
compounds. These disinfectant groups are widely used in the food industry being, their use, 
possible in the dilution agar method of MIC measurement according to Peyrat et al. (2007). 
Benzalkonium chloride (CB) and sodium hypochloride (SH) were tested on different 
concentrations. 
 
Table 8 - List of all antibiotics and disinfectants used for MIC evaluation. 
 
2.9.1. Preparation of biocide solutions 
Preparation of biocide solutions for agar dilution susceptibility testing (Table 6) was performed 
according to EUCAST- ESCMID (2000) and Wiegand et al. (2007).  
 
2.9.2. MIC procedure  
The MIC was defined as the lowest concentration of an antimicrobial agent that inhibited visible 
growth completely. MIC procedure was performed according to EUCAST- ESCMID, 2000. 
Bacterial strains were grown on Columbia Blood agar (bioMerieux), supplemented with  
5% horse blood and incubated at 42°C for 48h under microaerobic conditions  
(5% O2, 10% CO2 and 85% N2) in gas tight containers. After growth bacterial strains were 
resuspended on saline steril water reaching 0.5 McFarland and spoted on Mueller-Hinton blood 
agar (Scharlau), supplemented with 5% horse or sheep blood (bioMerieux) and incorporated 
with each concentration of each antimicrobial under evaluation.  
 
Campylobacter strains were incubated at 42°C for 48h under microaerobic conditions  
(5% O2, 10% CO2 and 85% N2) in gas tight containers. Spotting was performed on a laminar 
flow class II cabinet (Telstar). Staphylococcus aureus ATCC 25923, Enterococcus faecalis 
ATCC 29212 and Campylobacter jejuni NCTC11168, for which quality control ranges have been 
established, were included as quality control strains (according to CLSI - Clinical and Laboratory 
Standards Institute).  
 
Ranges for antibiotic concentration for susceptibility testing were chosen according to  
Payot et al. (2002), Payot et al. (2004), Peyrat et al.(2007),  CA-SFM (2010), (table 9). Ranges 
Biocide Supplier Solvents Storage 
Antibiotics 
Ciprofloxacin AppliChem Hydrochloride 0,1M, pH4 4ºC, 2 weeks protected from light 
Erythromycin AppliChem Ethanol 95% 4ºC, 1 weeks protected from light 
Gentamicin Sigma-Aldrich Water 4ºC, 6 months protected from light 
Tetracycline Sigma-Aldrich Water 4ºC, 1 week protected from light 
Disinfectants 
CB Sigma-Aldrich Water 4ºC, 3months protected from light 
HS Sigma-Aldrich Water 4ºC, 3months protected from light 
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for disinfectant concentration susceptibility testing were chosen according to Peyrat et al. (2007) 
with modifications. The breakpoints adopted for MIC interpretation are presented on Table 10, 
according to CA-SFM (2010). 
 
Table 9 - Comprehensive resume concerning the range of antibiotic and disinfectant concentrations under 
evaluation (E, erythromycin; CIP, ciprofloxacin; GM, gentamicin; TE, tetracycline; BC, benzalkonium 
chloride and HS, sodium hipochloride). Grey areas represent range concentrations for which MICs were 
performed. White areas represent concentrations not tested by MIC in the present work.  
µg/mL 0.03 0.06 0.125 0.250 0.5 1 2 4 8 16 32 64 128 256 512 
Antibiotics 
E                
CIP                
GM                
TE                
Disinfectants 
BC                
SH                
 
Table 10 – Breakpoints for MIC interpretation according to CA-SFM, 2010 
Antibiotics 
Breakpoints mg/L 
S I R 
Gentamicin ≤2 2-4 >4 
Cirpofloxacin ≤0.5 0.5-1 >1 
Erythromycin ≤1 1-4 >4 
Tetracycline ≤4 4-8 >8 
 
2.10. Efflux pump: the efflux pump inhibitor  
The efflux system CmeABC is a key player for intrinsic antibiotic resistance and is also required 
for the acquired resistance to fluoroquinolones. In order to determine the effect of this efflux 
pump in ciprofloxacin resistance different concentrations of an efflux pump inhibitor  
Phe-Arg-β-aphthylamide, EPI – PAβN was incorporated alongside the different ciprofloxacin 
concentrations previously mentioned on Mueller-Hinton blood agar (Scharlau), supplemented 
with 5% horse or sheep blood.  MICs were determined in the presence of the  
EPI Phe-Arg-β-naphthylamide (Sigma) at the following concentrations: 10, 20, 40, 60, and  
120 mg/ml according to Payot et al. (2004). 
 
2.11. Mismatch Amplification Mutation Assay-Polymerase Chain 
Reaction 
In order to determine the presence or absence of the point mutations attributed to high- level 
erythromycin and ciprofloxacin resistance in both C. jejuni (n=26) and C. coli (n=54) an 
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alternative inexpensive, rapid, accurate protocol to nucleotide sequencing was introduced: 
Mismatch Amplification Mutation Assay - Polymerase Chain Reaction (MAMA-PCR). This PCR 
technique involves the use of a conserved forward primer and a reverse mutation detection 
primer to generate a PCR product that will be a positive indication of the presence of the target 
mutations. 
 
2.11.1. MAMA-PCR for erythromycin resistance point mutations 
MAMA-PCR assay proved to be a fast and easy method to detect the presence of the point 
mutations in the 23S rRNA genes to which high-level resistance to erythromycin has been 
attributed. The methodology, adopted from Alonso et al.(2005) with modifications, was the same 
for both C. jejuni (n=26) and C. coli (n=54) strains. One conserved forward primer, 23S rRNA–F 
(5'TTAGCTATGTTGCCCGTACCG3') was used in conjunction with the reverse mutation primer 
ERY2075-R (5'TAGTAAAGGTCCACGGGGTCG3') to detect A2075G mutation, and in parallel 
with ERY2074-R (5'AGTAAAGGTCCACGGGGTCTGG3') to detect A2074C mutation. In both 
reactions, an amplicon of 485 bp was expected as a positive indication of the occurrence of the 
point mutations. A positive PCR control from 16S rRNA gene of C. jejuni and C. coli was used in 
this MAMA-PCR assay that generated an 857 bp amplicon. 
 
The amplification was carried out in the following conditions: An initial denaturation step at 94ºC 
for 5 min, followed by 30 cycles of denaturation at 94ºC for 30 s, annealing at 59ºC for 30 s, and 
extension at 72ºC for 45 s, and a final extension at 72ºC for 5 min, were performed using a 
Doppio thermocycler (VWR, Belgium). The amplified PCR fragments were separated by 
electrophoresis at 80 volts for 50 minutes (VWR) on 1.5% agarose (SeaKem) gel and 
visualization was possible through LISCAO, ImageMaster (Pharmacia Biotech).  
 
Because no positive control strains were available several strains were screened for the 
presence of the point mutation A2075G. One strain carrying the mutation was selected, 
respective PCR products were purified using the QIAquick PCR Purification Kit  
(Qiagen, Valencia, CA, USA) was then sequenced (Stabvida): PCery. C. jejuni NCTC 11168 was 
used as a negative control strain. 
 
2.11.2. MAMA-PCR for ciprofloxacin resistance point mutations 
The protocol used for detection of mutations in the gyrA gene was derived from the method 
described by Zirnstein et al. (1999) and Payot et al. (2002) with modifications. A conserved 
forward primer CampyMAMAgyrA1 (5'TTAGCTATGTTGCCCGTACCG3') was used for both C. 
jejuni and C. coli but different reverse mutation detection primers were used for either strains: 
while CampyMAMA gyrA5 (5'TTAGCTATGTTGCCCGTACCG3') was used for the detection of 
the potential point mutation in C. jejuni Campygyrmut (5'TTAGCTATGTTGCCCGTACCG3') was 
used for C. coli. A conserved, forward primer and the reverse mutation detection primers, were 
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used together to generate a 265-bp PCR product that was a positive indication of the presence 
of the corresponding Thr86-to-Ile change in the C. jejuni GyrA. 
 
The amplification conditions were the same for both species, except for the annealing step, and 
was carried out in the following conditions: initial denaturation step at 94ºC for 5 min, followed 
by 30 cycles of denaturation at 94ºC for 30 s, annealing at 52ºC for 30 s for C. jejuni and 50ºC 
for C. coli, and extension at 72ºC for 45 s, and a final extension at 72ºC for 5 min, were 
performed performed using a Doppio thermocycler (VWR, Belgium). The amplified PCR 
fragments were separated by electrophoresis at 80volts for 50 minutes (VWR) on 1.5% agarose 
(SeaKem) gel.  
 
Because neither C. jejuni nor C. coli positive control strains were available, several strains were 
screened for the presence of the point mutation in the gyrA gene. One strain of each species 
carrying the mutation was selected. Respective PCR products were purified using the QIAquick 
PCR Purification Kit (Qiagen, Valencia, CA, USA) and sequenced (Stabvida): PCgyrAC.j and 
PCgyrAC.c. C. jejuni NCTC 11168 was used as a negative control strain.  
 
3. Results and discussion 
According to EFSA, campylobacteriosis has been the most commonly reported zoonosis, since 
2005. Portugal is yet to include itself on the EFSA’s European Union Member States (EU MSs) 
that notifies yearly occurring human campylobacteriosis cases. Although several articles have 
been published concerning Campylobacter infection in humans, in Portugal much is still to be 
done (Cabrita et al., 1992; CSSSC, 2002; Vicente et al., 2008) Portugal is, however, included in 
the MS countries that do provide data concerning the prevalence of Campylobacter strains on 
broiler batches and the subsequent prevalence of this bacteria on foodstuffs.  
 
The knowledge that Campylobacter spp., especially C. jejuni and C. coli, are considered to be 
the most frequent cause of human bacterial enteritis worldwide and that poultry meat is an 
important foodborne source, where campylobacters linger from broiler flocks till processed retail 
products, are now facts. Significant antibiotic resistance levels in Campylobacter spp. from 
human and animal sources has been reported and there is a growing, pressing need to better 
understand Campylobacter spp. antimicrobial resistance patterns and the reason they occur, in 
order to find alternative ways of controlling the prevalence of this bacteria in foodstuffs, namely 
in poultry meat and in humans (Mena et al., 2008, Vicente et al., 2008; ESFA journal, 2010). 
 
Sampling procedure was performed in order to attain as much strain differentiation as possible. 
 
23 
 
Figure 3 – Relative contribution of each identified Campylobacter species for the total number of isolates 
(N=258). 
3.1. Characterization of Campylobacter isolates for antibiotic resistance 
The relative contribution of each isolate origin to the final number of disc susceptibility tested 
isolates (N=258) was analyzed (Table 11). Over two thirds, 75%, of the tested isolates were of 
poultry meat origin while the remaining isolates, 25%, were of human origin, campylobacteriosis 
patients.  
 
Table 11 - Comprehensive resume of all the isolates initially used concerning: Isolates origin, number of 
isolates for each origin (nA), species identification and number of each species for each origin (nB). 
 
From the initial 258 strains, 43% were identified as Campylobacter jejuni (n=112) while 57% 
were Campylobacter coli strains (n=146) (Figure 3). According to Mena et al. (2008),  
Saenz et al. (2000) and Fraqueza, (2009), a higher occurrence of C. jejuni has been associated 
with poultry products, although such a tendency was not observed in this study. From the 193 
isolates from poultry meat products used, C. coli isolates accounted for 65% against the 35% 
for C. jejuni. Careful observation indicates that such results are due to C.coli considerably 
higher representativeness in retail samples, which overwhelms the relatively similar 
Isolate origin nA (nº of isolates) (%) Species 
nB (nº of each 
species) 
Extensive indoor production 
system samples 40 (16%) 
C. jejuni 22 
C. coli 18 
Organic production system 
samples 44 (17%) 
C. jejuni 27 
C. coli 17 
Intensive production system 
samples 43 (17%) 
C. jejuni 17 
C. coli 26 
Human patients samples 65 (25%) C. jejuni 45 C. coli 20 
Retail samples 66 (25%) C. jejuni 1 C. coli 65 
    
Totals 258 C. jejuni 112 C. coli 146 
43%
57%
C. jejuni C. coli
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representativeness of both species for the other three origins. For human isolates there seems 
to also be an expected predominance of C. jejuni, as reported by Saenz et al. (2000) and this 
was, in fact, the case: 69% versus 31% for C. coli.  
3.2. Extensive indoor production system samples origin strains  
From the total initial Campylobacter spp. isolates (N=258), 16% were from broiler samples of 
extensive indoor production system origin, n=40, (Table 11). After identification, 55% were 
attributed to C. jejuni (n=22, out of the 40 total extensive indoor isolates) while 45% were 
identified as C. coli (n=18, out of the total 40 extensive indoor isolates).  
 
In view of the results for disc susceptibility testing obtained for extensive indoor production 
system origin strains regarding each of the 11 antibiotics tested one can observe that β-lactams, 
(ampicilin and amoxacilin+clavulanic acid) alongside the fluoroquinolones, (nalidixic acid, 
ciprofloxacin, norfloxacin and ofloxacin) showed the highest levels of resistance, respectively: 
70% (n=28), 53% (n=21), 83% (n=33), 75% (n=30), 68% (n=27) and 58% (n=23) (Figure 4). 
Resistance levels for these antibiotics were all over 50% specially for both nalidixic acid and 
ciprofloxacin. Strains showed the highest susceptibility, 93% (n=37) to chloramphenicol. Similar 
resistant and susceptibility ratios were attained for tetracyclin, 38% resistance (n=15) and 
gentamicin, 45% resistance (n=18) which was also the result for trimetropim/sulphametoxazole. 
For the macrolide erythromycin, 30% (n=12) of the tested were resistant. Resistance to this 
antibiotic has been mainly attributed to the occurrence of point mutation at position 2075 in the 
23S rRNA.  Of the 12 (n=12) strains that tested resistant for erythromycin, 8 isolates were 
corroborated by the detection of the point mutation by RFLP-PCR. For the remaining strains, 
according to Kurinčič et al. (2007), absence of corroboration may be due to the occurrence of 
alternative mutations occuring at position 2074 in the 23S rRNA.  
 
Figure 4 – Frequency of resistant to susceptible isolates of Campylobacter from extensive indoor 
production system origin isolates after perfoming disc diffusion testing. AMP, ampicilin; AUG, 
amoxacilin/clavulanic acid; E, erythromycin; TE, tetracycline; C, chloramphenicol; GM, gentamicin; CIP, 
ciprofloxacin; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; STX, Trimethoprim/sulfamethoxazole.   
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Disc diffusion results revealed that only one strain was susceptible to all classes of tested 
antibiotics (Figure 5). Considering the definition of multiple resistance presented by SCENIHR 
(2009) stating that multiple resistance (MR) occurs when a bacterial strain is resistant to 
several, different antimicrobials or antimicrobial classes, we considered that multiple resistance 
occurs when resistance is found for more than 2 classes. The majority of isolates, 35% (n=14) 
were found to be resistant to a maximum of 4 classes of antibiotics, 5% (n=2) were resistant to 
5 classes of antibiotics and 8% (n=3) were resistant to 6 of the 7 classes tested. It is then safe 
to conclude that nearly half, 48% (n=19), of the tested isolates were multiple-resistant strains. 
No strain was found to be resistant to all 7 antibiotic classes under evaluation.  
 
Figure 5 - Extensive indoor production system origin isolates resistance to different antibiotic classes, 
identification of multiple drug resistant strains. 
 
Although no particularly staggering difference was observed between species, it is possible to 
scrutinize (Table 12) that C. coli isolates showed less resistance levels than its counterpart with 
the exception of tetracycline and norfloxacin. Considering C. jejuni’s resistance in broiler meat it 
was observed that, for the isolates in this study, resistance patterns were considerably higher 
for gentamicin, and erythromycin then those reported by the EFSA (2010) on antimicrobial 
resistance in zoonotic and indicator bacteria from animals and food in the European Union in 
2008. For gentamicin, a  resistance level for C. jejuni of 13% against the 55% resistant isolates 
was observed in this study. A considerable discrepency was also observed for erythromycin for 
which, instead of the 6% EFSA reported, resistance levels reached 32% of the tested isolates. 
Reported resistance levels for ciprofloxacin and nalidixic acid ranged from 31-100%, for these 
antibiotics resistance isolates settled for, respectively 86% and 82%. For tetracycline resistance 
levels attained in this study  were quite similar as the reported ones, 32% to 38%. 
 
2%
10%
20%
20%
35%
5%
8%
No resistance
Resistance to 1 class of antibiotics tested
Resistance to 2 classes of antibiotics tested
Resistance to 3 classes of antibiotics tested
Resistance to 4 classes of antibiotics tested
Resistance to 5 classes of antibiotics tested 
Resistance to 6 classes of antibiotics tested
Resistance to all antibiotic classes tested
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Table 12 – Summary of the results attained for the 11 tested antibiotics for C. jejuni and C. coli for 
extensive indoor production system isolates. nR, number of tested resistant strains for the mentioned 
antibiotics. 
Antibiotic 
C. jejuni (N=22) C. coli (N=18) 
nR/N (%) nR/N (%) 
Ampicilin 18/22 82% 10/18 56% 
Amoxacilin 14/22 64% 7/18 39% 
Erythromycin 7/22 32% 5/18 28% 
Tetracycline 7/22 32% 8/18 44% 
Chloramphenicol 2/22 9% 1/18 6% 
Gentamicin 12/22 55% 6/18 33% 
Ciprofloxacin 18/22 82% 12/18 67% 
Nalidixic acid 19/22 86% 14/18 78% 
Norfloxacin 14/22 64% 13/18 72% 
Ofloxacin 13/22 59% 10/18 56% 
Trimethoprim/sulfamethoxazole 11/22 50% 7/18 39% 
 
Caecum and carcass (breast skin) samples takes a representation of 23% (n=9) and 30% 
(n=12) respectively while breast meat has a 48% (n=19) contribution. No particular distinction, 
concerning antibiotic resistance, was observed, between strains, isolated from these different 
samples of extensive indoor production system.  
3.3. Organic production system samples origin strains  
From the total initial Campylobacter spp. strains (N=258), 17% were from broiler samples of 
organic production system origin (n=44, out of 258 total strains) (Table 11). 61% were attributed 
to C. jejuni (n=27, out of the 44 total organic strains) while 39% were C. coli (n=17, out of the 
total 44 organic strains). 
 
Disc susceptibility testing for organic production system origin strains, regarding each of the 11 
antibiotics tested revealed that most isolates were resistant to the fluoroquinoles used  
(Figure 6): Ciprofloxacin, 89%; Nalidixic acid, 91%; Norfloxacin, 89% and Ofloxacin, 84%. A 
previous study performed for isolates from organic production samples in the United States 
revealed the same, understandable paralelism between quinolone results although they came 
across much lower resistance patterns, 1% (Luangtongkum et al., 2006). The β-lactam 
ampicilin, as well as tetracycline had 73% resistant isolates (n=32) against the 5% and 52%, 
respectively, observed in the previously mentioned study. There was a considerable difference 
between the number of resistant strains for ampicilin (n=32) in comparisson to the number of 
resistant strains for amoxacilin/clavulanic acid, (n=19).  
 
Antibiotic resistance evaluation by disc diffusion testing was performed and the response of 
both species to the 11 antimicrobials tested. Regarding the general panorama, no greater 
difference was observed between species, C. coli showed higher levels of resistance when 
compared to C. jejuni with the exception of gentamicin (Table 13). 
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Figure 6 - Disc susceptibility testing for organic production system origin isolates. AMP, ampicilin; AUG, 
amoxacilin/clavulanic acid; E, erythromycin; TE, tetracycline; C, chloramphenicol; GM, gentamicin; CIP, 
ciprofloxacin; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; STX, Trimethoprim/sulfamethoxazole.     
C. coli isolates were particularly resistant to fluoroquinolones raging between 94%, for both 
ofloxacin and norfloxacin, to 100% for nalidixic acid and ciprofloxacin while C. jejuni resistance 
levels ranged from 70% for ofloxacin till 78% for nalidixic acid. Chloramphenicol had 
susceptibility levels of 41% (n=20), while 52% (n=23) of strains were 
trimethoprim/sulfamethoxazole susceptible. Gentamicin had the lowest resistance level, given 
that only 14% of tested strains were resistant. For erythromycin the exact same number of 
strains, n=12, were found to be resistant and susceptible while almost half, 46%, of the isolates 
were classified as intermediate. Of the 12 (n=12) strains that tested resistant for erythromycin, 
12 (n=12) were corroborated by the detection of the point muation by RFLP-PCR. 
 
Table 13 - Summary of the results attained for the 11 tested antibiotics for C. jejuni and C. coli for organic 
production system isolates. 
Antibiotic 
C. jejuni (N=27) C. coli (N=17) 
nR/N (%) nR/N (%) 
Ampicilin 18/27 67% 14/17 82% 
Amoxacilin 9/27 33% 10/17 59% 
Erythromycin 5/27 19% 7/17 41% 
Tetracycline 17/27 63% 14/17 82% 
Chloramphenicol 11/27 41% 8/17 47% 
Gentamicin 5/27 19% 1/17 6% 
Ciprofloxacin 20/27 74% 17/17 100% 
Nalidixic acid 21/27 78% 17/17 100% 
Norfloxacin 20/27 74% 16/17 94% 
Ofloxacin 19/27 70% 16/17 94% 
Trimethoprim/sulfamethoxazole 6/27 22% 5/17 29% 
 
According to Luangtongkum et al. (2006), a considerable decrease of antimicrobial resistance 
should be observed considering the practices performed for raising organic poultry. Isolates in 
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the present study went against such observations. Rodenburg et al. (2004), stated that although 
organic poultry is generally assumed to be safer and healthier, the fact that these animals have 
access to an outdoor run allows them to contact with wild birds, rodents, manure and various 
other Campylobacter resistant strain sources enabling the transmission of resistant strains to 
organic poultry infecting the entire flocks.  
 
Disc diffusion testing revealed that only one isolate was susceptible to all classes of antibiotics 
tested (Figure 7). The majority of strains, 27% (n=12) were found to be resistant to a maximum 
of 4 classes of antibiotics, 14% (n=6) were resistant to 5 classes of antibiotics and 11% (n=5) 
were resistant to 6 of the 7 classes tested. Over half the strains analyzed, 75% (n=33), of the 
tested strains were multiple-resistant strains. No strain was found to be resistant to all 7 
antibiotic classes under evaluation. Luangtongkum et al. (2006) also screened strains for 
multiple resistance concluding that, for broiler isolates of organic production system, only 7% of 
all tested strains showed to resist to 4 different antibiotic classes considerably less than the 
27% observed in this study. 
 
 
 
Figure 7 - Organic production system origin strains resistance to different antibiotic classes. Identification 
of multiple drug resistant strains. 
 
Caecum, carcass (breast skin) and breast meat samples took a representation of 21% (n=9); 
25% (n=11) and of 46% (n=24) respectively. No particular distinction, concerning antibiotic 
resistance, was observed between strains isolated from these different samples of organic 
production system although carcass (breast skin) samples showed a higher number of strains 
resistant to 2 of the classes of antibiotics evaluated, while caecum and breast meat showed 
multiple resistances, to 3 and 4 classes respectively. 
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3.4. Intensive production system samples origin strains  
Intensive production system samples had a contribution of 16% (n=43 out of the 258 total 
strains) isolates. C. jejuni accounted for 40% (n=17, out of the 43 total intensive strains) while 
61% were identified as C. coli (n=26, out of the total 43 intensive strains). 
 
Figure 8 - Relative contribution of each identified Campylobacter species for the total number of intensive 
production systems. 
 
In opposition to what was previously described by Mena et al. (2004), there was a higher 
occurrence of C. coli in comparison to C. jejuni for these isolates (Figure 8). Such a situation 
may be due to the restriction of sample size, questioning the representativeness of the data. 
3.5. Human stool samples origin strains 
From the total initial Campylobacter spp. strains (N=258), 25% were from human stool sample 
origin (n=65, out of 258 total strains) (Table 11).  
 
Stool sample origin strains were attained from 2008 till 2010 from patients from different 
Portuguese hospitals. More male isolates, 62%, than female, 38%, (male/female ratio = 1.6) 
were attained except for young adults, these were also the observations published by 
Gallay et al., 2007 who observed a male/female ratio of 1.2 with the exception of young adults 
(Figure 9). The distribution of Campylobacter spp isolates according to the gender and age of 
the patient revealed that the ages from 0 to 4 years were particularly affected as well as for 
adults from ages 15 till 54. It is worth considering the hypothesis that newborns and infants 
raise more concern to parents or caretakers and hence the increase amount of detection for this 
particular age group. 
 
Strain identification had been performed at INSA: 69% were C. jejuni (n=45, out of the 65 total 
human strains) while 31% were identified as C. coli (n=20, out of the total 65 human strains).  
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Figure 9 – Gender related Campylobacter spp. isolated from stool samples and the distribution 
of Campylobacter spp. isolates according to age and gender of patient, Portugal, 2008 – 2010. 
 
Disc diffusion testing made it possible to compare antibiotic resistance shown by both species in 
comparison to each other for the 11 antimicrobials tested (Table 14). Both species were entirely 
susceptible to chloramphenicol. Similarity between strains was also attained for ampicilin, 73% 
and 75% for C. jejuni and C. coli respectively, which was not what Gallay et al. (2004) found. In 
Gallay et al. (2004) study, ampicilin resistant level was higher than those observed in this study 
and were higher for C. jejuni (38%) in comparison to C. coli (15%). For fluoroquinolones, it was 
found in the present study that C. jejuni strains were tendencially more resistant then C. coli 
strains. For ciprofloxacin 84% C. jejuni isolates were resistant while 60% of C. coli isolates were 
resistant strains. 
 
Table 14 - Summary of the results attained for the 11 tested antibiotics for C. jejuni and C. coli for human 
stool sample isolates. 
Antibiotic 
C. jejuni (N=45) C. coli (N=20) 
nR/N (%) nR/N (%) 
Ampicilin 33/45 73% 15/20 75% 
Amoxacilin/clavulanic acid 18/45 40% 16/20 80% 
Erythromycin 8/45 18% 13/20 65% 
Tetracycline 23/45 51% 1/20 5% 
Chloramphenicol 0/45 0% 0/20 0% 
Gentamicin 4/45 9% 8/20 40% 
Ciprofloxacin 38/45 84% 12/20 60% 
Nalidixic acid 38/45 84% 16/20 80% 
Norfloxacin 31/45 69% 15/20 75% 
Ofloxacin 37/45 82% 16/20 80% 
Trimethoprim/sulfamethoxazole 28/45 62% 15/20 75% 
 
In Gallay et al. (2004) study the reverse occurred and much lower level of ciprofloxacin 
resistance were reported, with C. coli having higher levels of ciprofloxacin resistance, 42% 
against C. jejuni, 25%. On the one hand, results provided by Gallay et al. (2004) pertain to 
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human isolates from France and reported fluoroquinolone considerably lower resistance levels 
than those obtained in this study. On the other hand, the results attained in the present study 
approached the results provided by Vicente et al. (2008) that revealed an 81% resistant level to 
the fluoroquinolone ciprofloxacin. It is also worth mentioning the difference found for 
erythromycin. Engberg et al. (2001) reported that typically higher frequency of erythromycin 
resistance was found in C. coli than in C. jejuni. In this study, while 18% of C. jejuni strains were 
found to be resistant to this antibiotic against 65% of C. coli strains. A similar patter, although for 
lower levels of erythromycin resistance, was observed by Gallay et al. (2004): C. jejuni had a 
resistant level of only 1% to erythromycin, 13% C. coli isolates were erythromycin resistant. A 
similar but reverse occurrence can be observed for tetracycline, while this time C. coli had only 
1 strain resistant to tetracycline (5%) more than half of C. jejuni strains, 51%, had the resistant 
phenotype. Gallay et al. (2004) reported the opposite: 53% of C. coli isolates were resistant 
against the 29% C. jejuni resistant isolates. Also, particularly higher levels of gentamicin 
resistance were registered for C. coli human strains. It is worth adding that for most antibiotics, 
with the exception of tetracycline and gentamicin, which are included in classes that share the 
same bacterial primary target, C. coli had similar to higher levels of resistance when compared 
to C. jejuni. 
 
According to the results from disc susceptibility testing obtained for stool samples of human 
campylobacteriosis patients origin strains, regarding each of the 11 antibiotics tested one can 
observe that flouroquinolones had the highest level of resistance ranging from 71% for 
norfloxacin (n=46) to 83% for nalidixic acid (n=54). 77% (n=50) strains were resistant to 
ciprofloxacin and 82% were ofloxacin resistant, (n=53) (Figure 10). Vicent et al. (2008), came 
across a similar result concedering ciprofloxacin resistance: 80.5%.Comparatively, also the  
β-lactam ampicilin had relatively high levels of resistance, up to 74% (n=48) of human origin 
strains were ampicilin resistant while for amoxacilin/clavulanic acid resistance was as high as 
52%. For tetracycline and gentamicin results were quite uneven, 37% (n=24) and 19% (n=12) 
respectively. 34% (n=22) of tested human strains were susceptible to 
trimethoprim/sulfamethoxazole which was similar to erythromycin, 32% resistant isolates. To 
chloramphenicol strains were entirely, 100% (n=0) susceptible.Of the 21 (n=21) strains that 
tested resistant for erythromycin only 11 (n=11) were corroborated by the detection of the point 
mutation by RFLP-PCR. For the remaining strains, according to Kurinčič et al. (2007) absence 
of corroboration may be due to the occurrence of alternative mutations 
 
Antibiotic disc diffusion protocol performed for human strains made it possible to draw 
conclusions considering the occurrence of bacterial strains resistant to several, different 
antimicrobial classes (Figure 11). Multiple resistance occurred for 75% of human strains (n=49). 
Although no strains were found to be entirely susceptible none were also found to be resistant 
to more than 5 classes of antibiotics.  
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Figure 10 - Disc susceptibility testing for human stool origin strains. AMP, ampicilin; AUG, 
amoxacilin/clavulanic acid; E, erythromycin; TE, tetracycline; C, chloramphenicol; GM, gentamicin; CIP, 
ciprofloxacin; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; STX, Trimethoprim/sulfamethoxazole.   
 
Figure 11 - Extensive indoor production system origin isolates resistance to different antibiotic classes, 
identification of multiple drug resistant strains. 
 
The majority of strains were resistant to a maximum of 3 antibiotic classes, 34%. Multiple 
resistances in humans is a serious matter due to the fact that infections in humans reflect both 
foodstuffs, mainly poultry meat, contamination with multiple drug resistance strains and the 
potential hazard of fail on good practice utilization of antibiotic at animal production level and 
human prescription and consumption. Gallay et al. (2004) reported that 58% of Campylobacter 
isolates were resistant to 1 or more drugs. This number is approximately half of what we 
attained in the present study. It was also reported by Gallay et al. (2004) that 20% were 
resistant to 3 or more antibiotics while in the present study 20% accounts for little less than one 
third of isolates resistant to 3 or more antibiotics. 
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3.6. Retail origin strains 
From the total initial Campylobacter spp. strains (N=258), 25% were from retail origin  
(n=65, out of 258 total strains) (Table 11). After species identification 2% were attributed to  
C. jejuni (n=1, out of the 66 total retail strains) while 99% were identified as C. coli (n=65, out of 
the total 66 retail strains). C. jejuni contribution was discarded at this point for further purposes. 
 
Disc diffusion method for the 11 antimicrobials tested was performed (Figure 12). Considering 
the absence of C. jejuni strains disc diffusion test results were performed for C. coli. Similar high 
resistance patterns were observed between the fluoroquinolones: nalidixic acid, 91% (n=59); 
ciprofloxacin, 92% (n=60); norfloxacin, 91% (n=60) and ofloxacin, 91% (n=59), these resistance 
levels were higher than those reported by Ge et al. (2003) and Kurinčič et al. (2005), who 
observed 41% and 35%, and 59% and 76% resistant isolates to respectively nalidixic acid and 
ciprofloxacin. Mena et al. (2004) did find fluoroquinolone resistant patterns that best resembled 
those attained in this study. The β-lactams, ampicilin and amoxacilin/clavulanic acid had similar 
resistance patterns, respectively, 49% (n=32) and 39%(n=25). Staggering was the difference 
between the results for tetracyclin, 91% (n=59) and gentamicin, 6% (n=4) due to the fact that 
both antimicrobial share primary targets. C. coli was almost entirely susceptible to 
chloramphenicol showing a 95% (n=62) susceptibility to the phenicol. Of the 27 strains that 
tested resistant for erythromycin 15 were corroborated by the detection of the point mutation by 
RFLP-PCR. This correspondes to a lower number of erythromycin resistant isolates than the 
54% reported by Ge et al. (2003). One of the tested strains was phenotypically intermediate 
although it carried the mutation.  
 
Figure 12 - Disc susceptibility testing for processed poultry retail products. AMP, ampicilin; AUG, 
amoxacilin/clavulanic acid; E, erythromycin; TE, tetracycline; C, chloramphenicol; GM, gentamicin; CIP, 
ciprofloxacin; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; STX, Trimethoprim/sulfamethoxazole.   
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Results considering the occurrence of bacterial strains resistant to several different antimicrobial 
classes: multiple resistance, were acquired by performing antibiotic disc diffusion protocol for 
retail strains (Figure 13). Multiple resistance occurred for 83% of retail strains (n=54). No 
strains were found to be entirely susceptible to every class of antimicrobials tested. 20% (n=13) 
of tested strains were found to be resistant to more than 5 classes of antibiotics. The majority of 
strains were resistant to a maximum of 4 antibiotic classes, 37%. Resistance to the whole 
panoply of tested antibiotics, 7 distinct classes, was found for 2 strains (n=2), 3%. One might 
assume that such observations may be due to the fact that such isolates are subjected to 
various types of meat products preservatives and therefore developing cross-resistance to 
antibiotics. 
 
 
 
Figure 13 - Processed poultry retail products resistance to different antibiotic classes, identification of 
multiple drug resistant strains. 
At a glance, results concerning broiler, human and retail samples strain resistance to 7 different 
classes of antibiotics are summarized in Tables 15 and 16.  
 
Table 15 – Comprehensive resume for antibiotic resistance to the 7 tested antibiotic classes for C. jejuni 
isolates from broiler, human and retail origin. ND, not determined. 
 AMP E TE C GM CIP STX 
nR/N %R nR/N %R nR/N %R nR/N %R nR/N %R nR/N %R nR/N %R 
EIPS 18/22 82 7/22 32 7/22 32 2/22 9 12/22 55 18/22 82 11/22 50 
OPS 18/27 67 5/27 19 17/27 63 11/27 41 5/27 19 20/27 74 6/27 22 
HS 33/45 73 8/45 18 23/45 51 0/45 0 4/45 9 38/45 84 28/45 62 
R ND 
 
According to EFSA report (2010) on antimicrobial resistance in zoonotic and indicator bacteria 
from animals and food in the European Union in 2008 for C. jejuni isolates from broiler meat 
provided by six MSs revealed that resistance to tetracycline was 38% for the reporting MS 
group, with the highest occurrence in Portugal (73%). This work tested strains that showed 
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resistance levels of 63% for organic strains. EFSAs reported resistance levels to erythromycin 
and gentamicin of 6% and 13%, respectively, this work tested strains had resistance levels of 
32% and 55%. The resistance levels for ciprofloxacin at reporting MS group level was 46% 
compared with 82% attained in this work. Although for some of the reposting countries 
ciprofloxacin resistance varied between 31% and 100%. Attained results, although staggering 
alarming when compared with the DANMAP, (2009), do actually generally comply with the 
observations of Sáenz et al. (2000) for Spanish strains or Petozzi et al. (2003) for northeastern 
Italy. This situation agrees with the already identified with the different geographical 
Campylobacter spp. isolation/ resistance patterns throughout Europe where northern countries 
appear less afflicted than their southern counterparts. 
 
Table 16 - Comprehensive resume for antibiotic resistance to the 7 tested antibiotic classes for C. coli 
isolates from broiler, human and retail origin 
 AMP E TE C GM CIP STX 
nR/N %R nR/N %R nR/N %R nR/N %R nR/N %R nR/N %R nR/N %R 
EIPS 10/18 56 5/18 28 8/18 44 1/18 6 6/18 33 12/18 67 7/18 39 
OPS 14/17 82 7/17 41 14/17 82 8/17 47 1/17 6 17/17 100 5/17 29 
HS 15/20 75 13/20 65 1/20 5 0/20 0 8/20 4 12/20 60 15/20 75 
R 32/65 49 26/65 40 59/65 91 3/65 5 4/65 6 60/65 92 48/65 74 
 
Regarding the general panorama for isolates susceptibility testing of broiler meat products of 
extensive indoor production and organic production systems and retail processed products, 
there seemed to be a slight tendency for extensive indoor isolates to have a higher susceptibility 
to the different antibiotics tested in comparison to organic production systems. Such observation 
was stronger, regarding results for the fluoroquinolone, ciprofloxacin for which 89% of organic 
isolates were resistance against the 75% resistant isolates detected for extensive indoor 
isolates. Such tendency was even more evident for tetracycline for which 37.5% of extensive 
indoor isolates were found to be resistant against the 73% of isolates. For macrolide resistance 
the opposite was regarded as, 27% of organic isolates were resistant versus 75% for extensive 
indoor production. Ciprofloxacin and tetracycline resistance was higher for retail processed 
poultry reaching resistance levels of 92% and 91% respectively. For human strains a 77% 
fluoroquinolone resistance was observed which is relatively close to what was described by 
Vicente et al. (2008) and also by Engberg et al. (2001) for Spanish resistant isolated strains. 
Engberg et al. (2001) also stated that in these regions, where quinolone resistance is highly 
endemic and Campylobacter spp. predominate; fluoroquinolones should not be recommended 
for community-acquired bacterial diarrhea. 
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3.7. Effect on ciprofloxacin resistance of the efflux pump inhibitor for multiple 
resistance strains 
 
After performing disc susceptibility testing, 14 strains from each sample origin: Extensive indoor 
production system, organic production system, intensive production system and human stool, 
and 24 strains from retail poultry products origin were selected according to resistance profiles 
previously determined. For the present work we considered that multiple resistances occur 
when resistance is found for more than 2 antibiotic classes (ESCMID, 2011). Minimum inhibitory 
concentrations, MICs, were performed on each of the selected strains, for erythromycin, 
ciprofloxacin, tetracycline and gentamicin as well as for BC and SH. 
 
The putative contribution of an efflux pump on intrinsic and high levels of resistance was under 
evaluation at this point. The main efflux pump involved in fluoroquinolone resistance in 
Campylobacter has been characterized as a member of the RND superfamily  
(Fàbrega et al, 2008).  By adding an efflux-pump inhibitor (PAβN) one would conclude upon the 
contribution of an efflux pump, potentially the CmeABC, on antimicrobial resistance, specifically 
on ciprofloxacin resistance. In the revised literature, Payot et al. (2004); Cagliero et al. (2006); 
Hannula & Hänninen, (2008), among others there was a detailed description for macrolide 
resistance, namely erythromycin, and the effect of putative efflux pumps on the resistance 
patterns in Campylobacter spp.. For ciprofloxacin however, the amount of available information 
was somewhat restricted. 
3.7.1. Characterization of selected strains for antibiotic multiple resistance 
regarding genes and phenotypic expression 
 
Extensive indoor production system selected strains 
From the 14 selected strains of extensive indoor production system origin, 8 were  
C. jejuni (57%) and 6 were C. coli (43%). After MIC testing was performed for both antibiotics 
and disinfectants it was observed that the 14 selected strains were actually completely 
susceptible to gentamicin, erythromycin and tetracycline (Table 17). Twelve of the 14 tested 
strains were ciprofloxacin resistant strains and the point mutation responsible for alteration of 
gyrA was found for all phenotypically ciprofloxacin resistant strains. Although 2 of these strains 
were identified has having the ability of growing on higher levels of ciprofloxacin concentration  
(till 32 mg/L) non were considered HLR.  These same two strains were also resistant to SH 
growing till 128mg/L concentration steps. Resistance to BC was found in 4 strains of which 2 
coincided with SH and ciprofloxacin resistance. One strain was simultaneously resistant to 
higher concentration levels ciprofloxacin (32 mg/L), BC (4 mg/L) and SH (128 mg/L). 
 
Organic production system selected strains 
From the 14 selected strains of organic production system origin, 3 were C. jejuni (n=3, 21%) 
and 11 were C. coli (n=11, 79%). After performing MICs for both antibiotics and disinfectants it 
was observed that for both tetracycline and gentamicin susceptibility was found for all tested 
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strains (n=14 of N=14) (Table 18). The exact reverse situation was found for erythromycin for 
which all strains were evaluated as resistant. For the fluoroquinolone ciprofloxacin, 4 strains 
were practically entirely susceptible to the antibiotic, 6 were borderline susceptible considering 
that growth stopped at 0.5 mg/L, and 4 strains were found to be resistant, these resistant strains 
stopped growing between 8mg/L and 512mg/L. All of these strains carried the gyrA point 
mutation but only 3 were HLR. As far as the disinfectants are concerned only one strain was 
resistant to both. This one strain though, strain B1, showed resistance levels as high as 4mg/L 
for the quaternary ammonium BC and even higher for SH, 512 mg/L. B1 also persisted in the 
presence of 512 mg/L of ciprofloxacin and 128 mg/L for erythromycin. 
 
Table 17 - Comprehensive resume for extensive production strains (EI), regarding gene and biocide 
resistance phenotypic expression. C.c, C. coli; C.j, C. jejuni; G, gentamicin; TE, tetracycline; E, 
erythromycin; CIP, ciprofloxacin; BC, benzalkonium chloride; SH, sodium hypochloride. ERY2074/2075 
point mutation for erythromycin resistance; gyrAMUT for ciprofloxacin resistance. Red stands for resistant, 
green for susceptible; -/- refers to not detected/not detected; -/+, not detected/ detected. 
 Strains 
 EI1 EI2 EI3 EI4 EI5 EI6 EI7 EI8 EI9 EI10 EI11 EI12 EI13 EI14 
Specie C.c C.c C.j C.j C.c C.c C.c C.j C.j C.j C.c C.j C.j C.j 
G               
TE               
E               
CIP               
BC               
SH               
ERY2074/2075 -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 
gyrA MUT - + - + + + + + + + + + + + 
 
Table 18 - Comprehensive resume for organic production strains (O), regarding gene and antimicrobial 
resistance phenotypic expression. C.c, C. coli; C.j, C. jejuni; G, gentamicin; TE, tetracycline; E, 
erythromycin; CIP, ciprofloxacin; BC, benzalkonium chloride; SH, sodium hypochloride. ERY2074/2075 
point mutation for erythromycin resistance; gyrAMUT for ciprofloxacin resistance. Red stands for resistant, 
green for susceptible; -/- refers to not detected/not detected; -/+, not detected/ detected and HLR, high 
level resistance. 
 Strains 
 O1 O2 O3 O4 O5 O6 O7 O8 O9 O10 O11 O12 O13 O14 
Species C.c C.j C.c C.c C.c C.c C.c C.c C.c C.c C.c C.j C.j C.c 
G               
TE               
E HLR              
CIP HLR   HLR   HLR        
BC               
SH               
ERY2074/2075 -/+ -/+ -/- -/+ -/+ -/- -/- -/- -/- -/- -/- -/+ -/- -/+ 
gyrA MUT + + - + + - + - - - + - - - 
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Intensive production system selected strains 
From the 14 selected strains of intensive production system origin, 6 were C. jejuni (n=6, 43%) 
and 8 were C. coli (n=8, 57%). All strains were susceptible to gentamicin and resistant to 
ciprofloxacin, till 16mg/L, although none were classified as HLR. Five strains were resistant to 
tetracycline growing even at antibiotic concentrations of 64mg/L and 3 strains, all HLR, were 
erythromycin resistant (Table 19). The same 2 strains were resistant to both disinfectants 
growing till 64mg/L for SH and till 4mg/L for BC. Strain I14 was resistant to all antimicrobials 
tested except for gentamicin.  
 
Table 19 - Comprehensive resume for intensive production strains (I), regarding gene and antimicrobial 
resistance phenotypic expression. C.c, C. coli; C.j, C. jejuni; G, gentamicin; TE, tetracycline; E, 
erythromycin; CIP, ciprofloxacin; BC, benzalkonium chloride; SH, sodium hypochloride. ERY2074/2075 
point mutation for erythromycin resistance; gyrAMUT for ciprofloxacin resistance. Red stands for resistant, 
green for susceptible; -/- refers to not detected/not detected; -/+, not detected/ detected; HLR, high level 
resistance. 
 Strains 
 I1 I2 I3 I4 I5 I6 I7 I8 I9 I10 I11 I12 I13 I14 
Specie C.c C.c C.j C.j C.j C.c C.c C.c C.j C.j C.j C.c C.c C.c 
G               
TE               
E           HLR HLR  HLR 
CIP               
BC               
SH               
ERY2074/2075 -/- -/- -/+ -/- -/- -/- -/- -/- -/- -/- -/+ -/+ -/- -/+ 
gyrA MUT + + + + + + + + + + + + + + 
 
Human stool samples selected strains 
From the 14 selected strains of human stool origin, 8 were C. jejuni (57%) and 6 were C. coli 
(43%). Once again all strains were susceptible to gentamicin (Table 20). Four of the 5 strains 
resistant to tetracycline grew till antibiotic concentration reached 64mg/L. Of the 14 strains 
tested 2 were shyly resistant to erythromycin while all strains were resistant to ciprofloxacin. 
Only one strain was resistant to the effect of the disinfectants, the same strain for both BC and 
SH. This strain was also resistant to ciprofloxacin. 
 
Retail selected samples 
All the 24 selected strains of retail origin were C. coli identified strains. Amongst them was no 
gentamicin resistant strain. 7 out of the 24 tested strains were resistant to tetracycline and 11 
showed resistance levels to erythromycin (tables 21 and 22). Only 3 strains of the selected 24 
were susceptible to ciprofloxacin while only 3 were susceptible to the disinfectant BC. All strains 
were resistant do SH. 
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Table 20 - Comprehensive resume for human strains (H), regarding gene and antimicrobial resistance phenotypic 
expression. C.c, C. coli; C.j, C. jejuni; G, gentamicin; TE, tetracycline; E, erythromycin; CIP, ciprofloxacin; BC, 
benzalkonium chloride; SH, sodium hypochloride. ERY2074/2075 point mutation for erythromycin resistance; gyrAMUT 
for ciprofloxacin resistance. Red stands for resistant, green for susceptible; -/- refers to not detected/not detected; -/+, 
not detected/ detected. 
 Strains 
 H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 H13 H14 
Specie C.j C.j C.j C.j C.j C.c C.c C.c C.c C.c C.c C.j C.j C.j 
G               
TE               
E               
CIP               
BC               
SH               
ERY2074/2075 -/- -/- -/- -/- -/- -/- -/- -/- -/+ -/- -/- -/+ -/- -/- 
gyrA MUT + + + + + + + + + + + + + + 
 
Table 21 - Comprehensive resume for processed poultry retail strains regarding gene and antimicrobial resistance 
phenotypic expression. C.c, C. coli; C.j, C. jejuni; G, gentamicin; TE, tetracycline; E, erythromycin; CIP, ciprofloxacin; 
BC, benzalkonium chloride; SH, sodium hypochloride. ERY2074/2075 point mutation for erythromycin resistance; 
gyrAMUT for ciprofloxacin resistance. Red stands for resistant, green for susceptible; -/- refers to not detected/not 
detected; -/+, not detected/ detected. 
 Strains 
 R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 
Specie C.c C.c C.c C.c C.c C.c C.c C.c C.c C.c C.c C.c 
G             
TE             
E             
CIP             
BC             
SH             
ERY2074/2075 -/+ -/- -/- -/- -/- -/- -/+ -/- -/- -/+ -/+ -/- 
gyrA MUT + - - + + + + + + + + - 
 
Table 22 – Continuation of the comprehensive resume for processed poultry retail strains regarding gene and 
antimicrobial resistance phenotypic expression. C.c, C. coli; C.j, C. jejuni; G, gentamicin; TE, tetracycline; E, 
erythromycin; CIP, ciprofloxacin; BC, benzalkonium chloride; SH, sodium hypochloride. ERY2074/2075 point mutation 
for erythromycin resistance; gyrAMUT for ciprofloxacin resistance. Red stands for resistant, green for susceptible; -/- 
refers to not detected/not detected; -/+, not detected/ detected; HLR, high level resistance. 
 Strains 
 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 
Specie C.c C.c C.c C.c C.c C.c C.c C.c C.c C.c C.c C.c 
G             
TE             
E             
CIP        HLR     
BC             
SH             
ERY2074/2075 -/- -/- -/+ -/- -/+ -/+ -/- -/+ -/- -/+ -/+ -/+ 
gyrA MUT + + + + + + + + + + + + 
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Special consideration was taken for the results concerning erythromycin and ciprofloxacin 
resistance primarily due to the fact that both these antibiotics are used as therapeutic agents 
when human Campylobacter infection so requires. According to Mammelli et al. (2005),  
Payot et al. (2004) and Kurinčič et al. (2007) Campylobacter isolates exhibit two different 
phenotypes regarding erythromycin and ciprofloxacin resistance: High-level resistant (HLR) and 
low-level resistant (LLR). According to Mammelli et al. (2005), LLR designation is attributed to 
strains with growth levels for borderline breakpoints values as defined by CA-SFM (2009), 
therefore LLR erythromycin strains would stop growing at 4mg/L and LLR ciprofloxacin strains 
stop growing at 1 mg/L. HLR was attributed to strains that persisted till and beyond 64 mg/L for 
both the antibiotics mentioned. Considering the total 80 selected strains from different origins, 
83% (n=66) were of poultry origin and 18% (n=14) were of human origin. Erythromycin HLR 
was attributed to 4 strains, 1 of organic system origin and 3 of intensive production system.  
Erythromycin LLR resistance was not attributed to any of the tested strains. Ciprofloxacin HLR 
was identified in 4 of the total 80 selected strains: 3 of organic production system and 1 of retail 
sample origin. No HLR strains for either antibiotic were detected for human strains. Once more 
no LLR ciprofloxacin resistant strains were identified among the total selected strains. 
 
As described by Payot et al. (2004), while none carried the A2074G, all the erythromycin HLR 
strains carried the point mutation A2075G, detected by MAMA-PCR. The latter is one of the 
most predominant mutations among the erythromycin-resistant strains. We found, however, in 
the present study, that the occurrence of such point mutation is not exclusive of HLR strains 
given that the mutation was also detected for erythromycin resistant, but not HLR, strains. 
Phenotypically identified resistant isolates that did not carry neither point mutations, 2074 nor 
2075, were also identified. The occurrence of these resistant phenotypes may be attributed to 
the occurrence other, alternative, resistance mechanism, as described by  
Gibreel & Taylor (2006). A high level of antimicrobial resistance, especially for sodium 
hypochloride, was generally observed among strains (n=31) and more so for processed poultry 
meat retail products, for which all strains were HS resistant. This may be due to the fact that this 
disinfectant is widely used along the meat processing chain. Strains frequently come in contact 
with this compound and in time developed resistance to it (Sprenger, 1993; Moore et al., 2006). 
Tested strains showed resistance levels that ranged from 0 to 512mg/L.  11 of the tested strains 
were benzalconium chloride resistant. All strains resistant to the quaternary ammonium 
compound were also resistant to sodium hypochloride. 
 
It is also worth mentioning the occurrence of a quite evident parallelism between ciprofloxacin 
resistance and biocide resistance. Cross-resistance though is yet to be corroborated leaving the 
question of antibiotic resistant by disinfectant molecules still open for evidences. 
3.7.2. Efflux pump inhibition effect on ciprofloxacin resistant strains 
The existence of an efflux pump responsible for the extrusion of different compounds, including 
antibiotics and disinfectants is now a generally accepted fact. The pump is constitutively 
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expressed in wild type Campylobacter contributing to intrinsic resistance. The efllux pump 
inhibitor, phenylalanine arginine β-naphthylamide (PAβN) has been described as an efficient 
EPI, restoring erythromycin- and ciprofloxacin- susceptibility to resistant Campylobacter strains 
(Martinez & Lin, 2006). The effect of the efflux pump on ciprofloxacin resistance was tested in 
the present study. Ciprofloxacin resistance has been attributed, by several authors:  
Charvalos et al., (1995); Häninnen & Hannula, (2007), to the occurrence of point mutations in 
the gyrA gene, the molecular target of these agents. Such mutations include specific point 
mutations leading to substitutions at Ala-70, Asp-90 and Thr-86, being the latter the most 
frequently detected. Point mutations are generally regarded as responsible for HLR profiles 
while LLR or intrinsic resistance is associated with the presence of efflux pumps that actively 
extrude biocidal compounds (Mamelli et al., 2005). 
 
Intensive production system selected strains 
For all 10 ciprofloxacin resistant strains even the presence of a low PAβN dose of 10mg/L was 
sufficient to entirely restore ciprofloxacin susceptibility (Figure 14). Two of these strains were 
able to grow at a ciprofloxacin concentration of 32 mg/L even for more one-fold of EPI inhibitor 
concentration maintaining the resistant phenotype. At 40mg/L of inhibitor concentration 
susceptibility was restored. A similar outcome was reported by Payot et al. (2004) for which 
optimal inhibition was obtained with 40 mg/l of EPI. 
 
Figure 14 – Efflux pump inhibitor tested concentrations (0mg/L; 10mg/L; 20mg/L; 40mg/L; 60mg/L and 
120mg/L) for the 14 selected extensive indoor strains at ciprofloxacin concentrations raging from 0.03mg/L 
till 512mg/L.   
 
Organic production system selected strains 
The same pattern was observed for organic production system selected strains for which 3 
strains were identified as ciprofloxacin HLR. However, for this HLR strains susceptibility was not 
restored even at PAβN concentrations as high as 120mg/L (Figure 15). This was not an 
expected outcome for to our knowledge 40 mg/L, as described by Payot et al. (2004) was the 
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optimal EPI, and by all means the maximum needed concentration for restoring ciprofloxacin 
susceptibility. To our knowledge there are no current reports covering this situation. Still, a 10 
mg/L concentration for the inhibitor was enough to restore susceptibility to all resistant strains. 
 
Figure 15 - Efflux pump inhibitor tested concentrations (0mg/L; 10mg/L; 20mg/L; 40mg/L; 60mg/L and 
120mg/L) for the 14 selected organic strains at ciprofloxacin concentrations raging from 0.03mg/L till 
512mg/L.   
 
Intensive production system selected strains 
Intensive production system selected strains had similar responses to those observed for 
organic production system strains except for the fact that, two strains, not classified as HLR still 
maintained resistance to ciprofloxacin till EPI concentrations of 60mg/L (Figure 16). only 
becoming slightly more sensitive to the antibiotics effect at the next fold concentration of  
120 mg/L at which one strain, still growing, became ciprofloxacin susceptible while the other 
maintain the resistant status. All resistant strains carried the point mutation responsible for  
Thr-86- Ile exchange.  
 
Human selected stool sample origin strains 
All human stool samples origin strains, were ciprofloxacin resistant and all carried the previously 
mentioned codon-exchange responsible point mutation in QRDR region. 2 high resistance, but 
not HLR strains, grew without subsiding, till inhibitor concentrations of 120 mg/L. Four other 
resistant strains grew in the presence of 10mg/L but such growth was completely abolish in the 
next one-fold step of 20 mg/L EPI concentration (Figure 17).  
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Figure 16 - Efflux pump inhibitor tested concentrations (0mg/L; 10mg/L; 20mg/L; 40mg/L; 60mg/L and 
120mg/L) for the 14 selected intensive strains at ciprofloxacin concentrations raging from 0.03mg/L till 
512mg/L.   
 
 
Figure 17 - Efflux pump inhibitor tested concentrations (0mg/L; 10mg/L; 20mg/L; 40mg/L; 60mg/L and 
120mg/L) for the 14 selected human strains at ciprofloxacin concentrations raging from 0.03mg/L till 
512mg/L.   
 
Retail selected samples 
Finally for the 24 retail selected samples one could observe that in the presence of the lowest 
tested EPI concentration of 10 mg/L strains stopped growing (Figure 18). By an EPI 
concentration of 20 mg/L only higher and HLR strains still grew in the presence of 120 mg/L 
PAβN concentrations.  
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Our results indicate that, even for those strains carrying the point mutation, Thr-86- Ile, to which 
higher levels of resistant are attributed, ciprofloxacin susceptibility was, in general, restored. 
Some strains that revealed higher but not HLR, also seem to resist high levels EPI. The growth 
persistence of these non ciprofloxacin HLR strains, even at higher inhibitor concentrations may 
be attributed to the fact that these strains, although not phenotypically classified as HLR carried 
other mutations besides the point mutation in the QRDR of gyrA responsible for the Thr-86-Ile 
modification or possessed alternative active efflux systems since many are only now being 
discovered and/or characterized (Hannula & Hänninen, 2008). 
 
 
Figure 18 - Efflux pump inhibitor tested concentrations (0mg/L; 10mg/L; 20mg/L; 40mg/L; 60mg/L and 
120mg/L) for the 14 selected retail strains at ciprofloxacin concentrations raging from 0.03mg/L till 
512mg/L.   
 
4. Conclusions 
As the incidence of Campylobacteriosis continues to rise so rises the amount of multiple 
resistant strains. This alarming situation constitutes a serious health burden for which there is a 
pressing need for the development of new and better report and control protocols harmonized 
throughout the European Union, and Portugal is no exception. 
 
The purpose of this work was the phenotypical and genotypical characterization of isolates from 
different origins: extensive indoor, organic and intensive production systems, human stool 
samples from patients with Campylobacteriosis and retail processed poultry products in order 
the perceive the general panorama regarding antimicrobial resistance in both poultry and 
human strains in Portugal. 
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From the total initial number of poultry, human and retail origin isolates, 43% were identified as 
Campylobacter jejuni while 57% were Campylobacter coli strains. Three fourths, 75%, of tested 
isolates were of poultry meat origin while the remaining isolates were of human 
Campylobacteriosis patients’ origin.  
 
For the total poultry, human and retail origin strains, was observed a high resistance frequency 
to fluoroquinolones antibiotic tested (between 58% and 92%). For erythromycin, 30% to 40% of 
studied isolates were resistant. Isolates revealed resistance levels of 6% to 45% for gentamicin. 
Resistance pattern for tetracycline ranged from 37% to 91%.  
 
Poultry strains of extensive indoor production system isolates had the lowest ciprofloxacin 
resistance level when compared to organic production systems. Retail product strains had the 
highest level of all ciprofloxacin resistance isolates; this may be due to the occurrence of 
cross-resistance between disinfectant and preservative molecules to which meat products are 
subjected. Observations made for fluoroquinolones were similar to those of tetracycline, with 
extensive indoor production system strains having the lowest resistance patterns when 
compared to both organic and retail samples. Once again retail samples had the highest level of 
resistance observed, 91% among meat poultry samples. For extensive indoor production 
samples erythromycin resistance was observed for 75% of isolates while 40% was found for 
retail isolates. 
 
Human isolates showed high level percentage of resistant isolates to all therapeutic 
alternatives. 37% of isolates were tetracycline resistant and more than 70% were resistant to 
ciprofloxacin. Although a small fraction of gentamicin resistant isolates were attained from 
human samples, making gentamicin an attractive alternative to antimicrobial therapy in humans, 
this antibiotic is highly toxic to humans, being both nephro and hepatotoxic, and thus its 
utilization is highly restricted. 
 
Multiple drug resistance was one of the major issues to be considered in the present work. We 
observed that for all tested isolates, most strains were settled at resistance to 4 or more 
antibiotic classes (quinolones, macrolides, tetracycline and β-lactamics) for each different origin.  
Multiple resistances occurred from 86% till 93% of tested strains. Human and retail strains had 
no completely susceptible strains.  
 
All the strains considered HLR for erythromycin and ciprofloxacin carried the respectively point 
mutations: A2075G and gyrA (Thr86Ile). However other resistance strains that were not HLR 
also carried the same mutations. The maximum MIC concentration attained for erythromycin 
was 128 mg/L and for ciprofloxacin was 512 mg/L and still growing. Both results pertained to an 
organic strain, O1. On average, the majority of strains were ciprofloxacin resistant between  
8 mg/L and 16 mg/L.  
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For biocide resistance tested, a parallelism was observed between some HLR ciprofloxacin 
strains and BC and SH resistance patterns. The maximum resistance concentration registered 
was 64 mg/L for BC and 512 mg/L of SH. Retail strains showed the highest levels, 100%, of 
resistance to the sodium hypochloride biocide. 
 
Considering the effect of the efflux pump inhibitor tested (PAβN) to ciprofloxacin resistance, the 
HLR strains persisted even when confronted with high level concentrations of 120mg/L. For the 
remaining strains susceptibility to ciprofloxacin was entirely restored between 10 mg/L and  
40  mg/L. 
 
In summary, the worldwide combination of data along with conventional and molecular 
epidemiological information, will allow for a better understanding of how antibiotic resistance is 
initiated, acquired and how such organisms may be transmitted to new animal and human 
hosts. Currently, the general inadequate use of antibiotics, such as quinolones and macrolides 
is a matter of grave concern due to its contribution to the acquisition of resistance in foodborne 
bacteria that potentially leads to limitations in the efficacy of such compounds in treating human 
infections. There appears to be a general tendency for antibiotic resistance rates to rise against 
several antibiotic agents and thus multiple resistance patterns to several classes of antibiotics 
are beginning to emerge and Portugal seems to be no exception. 
 
Future work should include the efflux pump inhibitor potential in overcoming antibiotic 
resistance, in prevention and control of Campylobacter infection in humans and animal 
reservoirs with a potential use as an alternative drug therapy. The effect of the efflux pump 
inhibitors on biocide resistance strains should be performed. Establishment of evidences 
corroborating the occurrence of cross-resistance between antibiotics and biocides is also in 
need of clarification, since the future interventions for Campylobacter control underlines the use 
of biocides on carcass decontamination besides their commun use on hygienization plans for 
equipments and premises on food Industry. New and more complete information is also needed 
regarding resistance patterns and mechanisms of protection associated with stress responses, 
such as biofilm development.   
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